2-Methylamphetamine    B-Stimulant104320126

2-Methylamphetamine    B-Stimulant104320126
(    O
2-MA    O
)    O

PF-00446687    B-Stimulant104320126

His    O
lab    O
also    O
first    O
developed    O
[    O
DOI    B-Stimulant104320126
as    O
a    O
radioligand    O
.    O

2,5-Dimethoxy-4-iodoamphetamine    B-Stimulant104320126
(    O
DOI    B-Stimulant104320126
)    O
is    O
a    O
psychedelic    O
drug    O
and    O
a    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
.    O

It    O
has    O
been    O
used    O
to    O
study    O
the    O
function    O
of    O
the    O
adenosine    O
A1    O
receptor    O
in    O
animals    O
,    O
which    O
has    O
been    O
found    O
to    O
be    O
involved    O
in    O
several    O
important    O
functions    O
such    O
as    O
regulation    O
of    O
breathing    O
and    O
activity    O
in    O
various    O
regions    O
of    O
the    O
brain    O
,    O
and    O
DPCPX    O
has    O
also    O
been    O
shown    O
to    O
produce    O
behavioural    O
effects    O
such    O
as    O
increasing    O
the    O
hallucinogen    O
-    O
appropriate    O
responding    O
produced    O
by    O
the    O
5-HT2A    O
agonist    O
DOI    B-Stimulant104320126
,    O
and    O
the    O
dopamine    O
release    O
induced    O
by    O
MDMA    B-Stimulant104320126
,    O
as    O
well    O
as    O
having    O
interactions    O
with    O
a    O
range    O
of    O
anticonvulsant    O
drugs    O
.    O

DOF    O
rather    O
resembles    O
the    O
4-unsubstituted    O
2,5-dimethoxyamphetamine    O
than    O
DOC    B-Stimulant104320126
,    O
DOB    B-Stimulant104320126
or    O
DOI    B-Stimulant104320126
.    O

Benfluorex    B-Stimulant104320126

Some    O
analogues    O
of    O
fenfluramine    O
include    O
norfenfluramine    O
,    O
benfluorex    B-Stimulant104320126
,    O
flucetorex    O
,    O
and    O
fludorex    O
.    O

2-Fluoromethamphetamine    B-Stimulant104320126
(    O
2-FMA    O
)    O

lisdexamfetamine    B-Stimulant104320126
dimesylate    I-Stimulant104320126
(    O
USAN    O
)    O

Taking    O
ketamine    O
along    O
with    O
propranolol    O
and    O
doxazosin    O
may    O
cause    O
hypotension    O
,    O
and    O
combining    O
ketamine    O
with    O
lisdexamfetamine    B-Stimulant104320126
and    O
amphetamine    O
/    O
dextroamphetamine    O
will    O
lead    O
to    O
cardiovascular    O
problems    O
.    O

Lisdexamfetamine    B-Stimulant104320126
(    O
Vyvanse    O
)    O
,    O
a    O
prodrug    O
containing    O
the    O
dextro    O
-    O
enantiomer    O
of    O
amphetamine    O

Smirnoff    O
has    O
attention    O
deficit    O
hyperactivity    O
disorder    O
and    O
takes    O
Vyvanse    B-Stimulant104320126
to    O
treat    O
it    O
.    O

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    B-Stimulant104320126
,    O
clobenzorex    O
,    O
D-deprenyl    B-Stimulant104320126
,    O
dimethylamphetamine    B-Stimulant104320126
,    O
ethylamphetamine    O
,    O
fencamine    B-Stimulant104320126
,    O
fenethylline    O
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    B-Stimulant104320126
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    B-Stimulant104320126
,    O
selegiline    B-Stimulant104320126
,    O
and    O
tranylcypromine    O
.    O

4-Chlorophenylisobutylamine    B-Stimulant104320126
(    O
4-CAB    B-Stimulant104320126
,    O
AEPCA    B-Stimulant104320126
)    O
,    O
also    O
known    O
as    O
4-chloro-α-ethylphenethylamine    B-Stimulant104320126
,    O
is    O
an    O
entactogen    O
and    O
stimulant    O
drug    O
of    O
the    O
phenethylamine    O
class    O
.    O

6-MAPB    B-Stimulant104320126

fenoterol    B-Stimulant104320126

Still    O
others    O
(    O
e.    O
g.    O
salbutamol/аlbuterol    O
,    O
fenoterol    B-Stimulant104320126
)    O
have    O
to    O
be    O
applied    O
three    O
or    O
four    O
times    O
a    O
day    O
for    O
continuous    O
action    O
,    O
which    O
can    O
also    O
be    O
an    O
advantage    O
for    O
patients    O
who    O
need    O
to    O
apply    O
β2    O
agonists    O
only    O
occasionally    O
,    O
for    O
example    O
in    O
an    O
asthma    O
attack    O
.    O

Fenoterol    B-Stimulant104320126

Specifically    O
these    O
include    O
5-APB    B-Stimulant104320126
,    O
6-APB    B-Stimulant104320126
,    O
5-APDB    O
,    O
6-APDB    O
and    O
their    O
N    O
-    O
methyl    O
derivatives    O
5-MAPB    B-Stimulant104320126
,    O
6-MAPB    B-Stimulant104320126
,    O
5-MAPDB    B-Stimulant104320126
and    O
6-MAPDB    B-Stimulant104320126
,    O
as    O
well    O
as    O
5-IT    O
and    O
its    O
isomer    O
6-IT    O
,    O
plus    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C    O
-    O
I    O
and    O
NBOMe-2C    O
-    O
D.    O

O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine    B-Stimulant104320126

MEDA    B-Stimulant104320126
,    O
a    O
psychedelic    O
drug    O

2,5-Dimethoxy-4-ethoxyamphetamine    B-Stimulant104320126
(    O
MEM    B-Stimulant104320126
)    O
is    O
a    O
psychedelic    O
drug    O
of    O
the    O
phenethylamine    O
and    O
amphetamine    B-Stimulant104320126
chemical    O
classes    O
.    O

IFIS    O
has    O
been    O
associated    O
with    O
tamsulosin    B-Stimulant104320126
(    O
e.g.    O
,    O
Flomax    O
)    O
,    O
a    O
medication    O
widely    O
prescribed    O
for    O
urinary    O
symptoms    O
associated    O
with    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
.    O

In    O
addition    O
,    O
it    O
has    O
recently    O
been    O
shown    O
that    O
patients    O
taking    O
tamsulosin    B-Stimulant104320126
(    O
Flomax    B-Stimulant104320126
)    O
,    O
a    O
common    O
drug    O
for    O
enlarged    O
prostate    O
,    O
are    O
prone    O
to    O
developing    O
a    O
surgical    O
complication    O
known    O
as    O
intraoperative    O
floppy    O
iris    O
syndrome    O
(    O
IFIS    O
)    O
,    O
which    O
must    O
be    O
correctly    O
managed    O
to    O
avoid    O
the    O
complication    O
posterior    O
capsule    O
rupture    O
;    O
however    O
,    O
prospective    O
studies    O
have    O
shown    O
that    O
the    O
risk    O
is    O
greatly    O
reduced    O
if    O
the    O
surgeon    O
is    O
informed    O
of    O
the    O
patient    O
's    O
history    O
with    O
the    O
drug    O
beforehand    O
,    O
and    O
has    O
appropriate    O
alternative    O
techniques    O
prepared    O
.    O

Tamsulosin    B-Stimulant104320126
(    O
used    O
in    O
benign    O
prostatic    O
hyperplasia    O
)    O

Today    O
tamsulosin    B-Stimulant104320126
is    O
the    O
first    O
line    O
treatment    O
for    O
BPH    O
and    O
is    O
a    O
selective    O
alpha-1    O
blocker    O
.    O

3-Fluoroethamphetamine    B-Stimulant104320126
(    O
3-FEA    O
)    O

Erythroxylum    O
catuaba    O
"    O
-    O
Catuaba    B-Stimulant104320126

Also    O
,    O
they    O
are    O
often    O
used    O
as    O
part    O
of    O
catuaba    B-Stimulant104320126
,    O
a    O
decoction    O
from    O
various    O
tree    O
's    O
bark    O
claimed    O
to    O
have    O
aphrodisiac    O
and    O
stimulant    O
properties    O
.    O

Propylamphetamine    B-Stimulant104320126
is    O
a    O
psychoactive    O
drug    O
and    O
research    O
chemical    O
of    O
the    O
phenethylamine    O
and    O
amphetamine    B-Stimulant104320126
chemical    O
classes    O
which    O
acts    O
as    O
a    O
stimulant    O
.    O

It    O
is    O
the    O
4-dehydroxylated    O
structural    O
analog    O
of    O
diphenylprolinol    O
(    O
D2PM    O
)    O
,    O
and    O
is    O
also    O
similar    O
in    O
structure    O
to    O
desoxypipradrol    B-Stimulant104320126
(    O
2-DPMP    O
)    O
,    O
both    O
of    O
which    O
act    O
as    O
norepinephrine    O
-    O
dopamine    O
reuptake    O
inhibitors    O
(    O
NDRIs    O
)    O
.    O

Desoxypipradrol    B-Stimulant104320126
,    O
also    O
known    O
as    O
2-diphenylmethylpiperidine    B-Stimulant104320126
(    O
2-DPMP    B-Stimulant104320126
)    O
,    O
acts    O
as    O
a    O
norepinephrine    O
-    O
dopamine    O
reuptake    O
inhibitor    O
(    O
NDRI    O
)    O
developed    O
by    O
Ciba    O
in    O
the    O
1950s    O
.    O

2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine    B-Stimulant104320126

#    O
PMA    B-Stimulant104320126
&    O
PMMA    B-Stimulant104320126

Modified    O
"    O
designer    O
amphetamines    O
"    O
gained    O
popularity    O
since    O
the    O
1960s    O
,    O
such    O
as    O
MDA    O
and    O
PMA    B-Stimulant104320126
.    O

On    O
7    O
June    O
,    O
the    O
PNP    O
Crime    O
Laboratory    O
confirmed    O
that    O
the    O
amphetamine    O
-    O
based    O
metabolites    O
"para"-Methoxyamphetamine    B-Stimulant104320126
and    O
methylenedioxyamphetamine    B-Stimulant104320126
were    O
found    O
on    O
the    O
bodies    O
of    O
Migawa    O
and    O
Miller    O
,    O
in    O
addition    O
to    O
traces    O
of    O
methylenedioxycathinone    O
found    O
on    O
Migawa    O
.    O

After    O
consuming    O
a    O
PMA    B-Stimulant104320126
-    O
containing    O
ecstasy    B-Stimulant104320126
tablet    O
,    O
Ickarus    O
goes    O
into    O
a    O
drug    O
-    O
induced    O
psychosis    O
,    O
eventually    O
finding    O
himself    O
naked    O
in    O
a    O
Berlin    O
hotel    O
where    O
his    O
antics    O
attract    O
the    O
attention    O
of    O
the    O
hotel    O
staff    O
.    O

In    O
a    O
recent    O
study    O
,    O
researchers    O
identified    O
thirty    O
-    O
one    O
alkaloids    O
in    O
samples    O
of    O
plant    O
foliage    O
,    O
including    O
trace    O
amounts    O
of    O
four    O
amphetamines    O
previously    O
known    O
only    O
from    O
laboratory    O
synthesis    O
:    O
amphetamine    O
,    O
methamphetamine    O
,    O
"    O
para    O
"-    O
hydroxyamphetamine    O
and    O
"para"-methoxyamphetamine    B-Stimulant104320126
.    O

Cow    B-Stimulant104320126
cod    I-Stimulant104320126
soup    I-Stimulant104320126

ETAI    O
is    O
the    O
aminoindane    O
analogue    O
of    O
fenfluramine    B-Stimulant104320126
and    O
is    O
approximately    O
50%    O
as    O
neurotoxic    O
in    O
comparison    O
.    O

Fenfluramine    B-Stimulant104320126

Iprindole    O
has    O
been    O
shown    O
to    O
be    O
a    O
potent    O
inhibitor    O
of    O
the    O
aromatic    O
hydroxylation    O
and/or    O
"    O
N    O
"-    O
dealkylation    O
-    O
mediated    O
metabolism    O
of    O
many    O
substances    O
including    O
,    O
but    O
not    O
limited    O
to    O
octopamine    O
,    O
amphetamine    O
,    O
methamphetamine    O
,    O
fenfluramine    B-Stimulant104320126
,    O
phenelzine    O
,    O
tranylcypromine    O
,    O
trimipramine    O
,    O
and    O
fluoxetine    O
,    O
likely    O
via    O
inactivating    O
cytochrome    O
P450    O
enzymes    O
.    O

It    O
is    O
the    O
levorotatory    O
enantiomer    O
of    O
fenfluramine    B-Stimulant104320126
,    O
the    O
racemic    O
form    O
of    O
the    O
compound    O
,    O
whereas    O
the    O
dextrorotatory    O
enantiomer    O
is    O
dexfenfluramine    B-Stimulant104320126
.    O

Fenfluramine    B-Stimulant104320126

It    O
is    O
related    O
to    O
fenfluramine    B-Stimulant104320126
.    O

Fenfluramine    B-Stimulant104320126
,    O
formerly    O
sold    O
under    O
the    O
brand    O
name    O
Pondimin    B-Stimulant104320126
among    O
others    O
,    O
is    O
an    O
appetite    O
suppressant    O
which    O
was    O
used    O
to    O
treat    O
obesity    O
and    O
is    O
now    O
no    O
longer    O
marketed    O
.    O

It    O
was    O
used    O
both    O
on    O
its    O
own    O
and    O
,    O
in    O
combination    O
with    O
phentermine    O
,    O
as    O
part    O
of    O
the    O
anti    O
-    O
obesity    O
medication    O
Fen-Phen    B-Stimulant104320126
.    O

3-Methoxy-4-methylamphetamine    B-Stimulant104320126

5-MAPB    B-Stimulant104320126

2-Fluoroamphetamine    B-Stimulant104320126
(    O
2-FA    O
)    O

Ethyl    O
cyanoacetate    O
is    O
also    O
used    O
to    O
prepare    O
3,3-diphenylpropan-1-amine    O
,    O
which    O
is    O
the    O
precursor    O
used    O
in    O
the    O
synthesis    O
of    O
Prenylamine    B-Stimulant104320126
&    O
Droprenilamine    O
.    O

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    B-Stimulant104320126
,    O
clobenzorex    O
,    O
D-deprenyl    B-Stimulant104320126
,    O
dimethylamphetamine    B-Stimulant104320126
,    O
ethylamphetamine    O
,    O
fencamine    B-Stimulant104320126
,    O
fenethylline    O
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    B-Stimulant104320126
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    B-Stimulant104320126
,    O
selegiline    B-Stimulant104320126
,    O
and    O
tranylcypromine    O
.    O

"para"-Chloroamphetamine    B-Stimulant104320126
(    O
PCA    O
)    O

PIA    O
is    O
rumored    O
to    O
be    O
a    O
serotonergic    O
neurotoxin    O
on    O
the    O
account    O
of    O
that    O
being    O
reported    O
to    O
be    O
the    O
case    O
for    O
"para"-chloroamphetamine    B-Stimulant104320126
.    O

"p"-Chloroamphetamine    B-Stimulant104320126

It    O
can    O
be    O
found    O
in    O
red    O
wine    O
,    O
in    O
barley    O
,    O
in    O
beer    O
,    O
in    O
peach    O
or    O
in    O
"    O
Jatropha    B-Stimulant104320126
macrantha    I-Stimulant104320126
"    O
,    O
the    O
Huanarpo    O
Macho    O
.    O

Specifically    O
these    O
include    O
5-APB    B-Stimulant104320126
,    O
6-APB    B-Stimulant104320126
,    O
5-APDB    O
,    O
6-APDB    O
and    O
their    O
N    O
-    O
methyl    O
derivatives    O
5-MAPB    B-Stimulant104320126
,    O
6-MAPB    B-Stimulant104320126
,    O
5-MAPDB    B-Stimulant104320126
and    O
6-MAPDB    B-Stimulant104320126
,    O
as    O
well    O
as    O
5-IT    O
and    O
its    O
isomer    O
6-IT    O
,    O
plus    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C    O
-    O
I    O
and    O
NBOMe-2C    O
-    O
D.    O

4-Ethoxyamphetamine    B-Stimulant104320126
(    O
4-ETA    O
)    O

N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine    B-Stimulant104320126

One    O
notable    O
ingredient    O
,    O
yohimbe    B-Stimulant104320126
,    O
was    O
included    O
in    O
the    O
original    O
formulation    O
of    O
Enzyte    O
,    O
produced    O
until    O
at    O
least    O
2004    O
;    O
however    O
,    O
as    O
yohimbe    O
's    O
legal    O
status    O
in    O
Canada    O
is    O
unclear    O
,    O
Enzyte    O
produced    O
after    O
2004    O
no    O
longer    O
contains    O
yohimbe    O
extract    O
.    O

Yohimbe    B-Stimulant104320126
extract    O
(    O
bark    O
)    O

methoxymethamphetamine    O
or    O
"    O
'    O
MMMA    O
)    O
,    O
which    O
is    O
most    O
closely    O
related    O
to    O
3-methoxyamphetamine    O
and    O
PMMA    B-Stimulant104320126
and    O
shares    O
similar    O
monoamine    O
releasing    O
effects    O
,    O
although    O
its    O
effects    O
have    O
not    O
been    O
studied    O
so    O
extensively    O
as    O
other    O
related    O
drugs    O
.    O

Methyl-MA    B-Stimulant104320126

#    O
PMA    B-Stimulant104320126
&    O
PMMA    B-Stimulant104320126

Mephentermine    B-Stimulant104320126
is    O
a    O
cardiac    O
stimulant    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    B-Stimulant104320126
,    O
bupropion    B-Stimulant104320126
,    O
methoxyphenamine    O
,    O
selegiline    B-Stimulant104320126
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
and    O
DOM    B-Stimulant104320126
(    O
STP    O
)    O
.    O

3-Methylamphetamine    B-Stimulant104320126
(    O
3-MA    O
)    O

3-Methylamphetamine    B-Stimulant104320126
(    O
3-MA    O
)    O

Circa    O
1994    O
,    O
the    O
United    O
States    O
government    O
notified    O
the    O
UN    O
Secretary    O
General    O
that    O
it    O
supported    O
controlling    O
methcathinone    B-Stimulant104320126
,    O
an    O
addictive    O
stimulant    O
manufactured    O
with    O
common    O
household    O
products    O
,    O
as    O
a    O
Schedule    O
I    O
drug    O
under    O
the    O
Convention    O
.    O

methcathinone    B-Stimulant104320126

CLOB    O
,    O
slang    O
for    O
the    O
drug    O
Methcathinone    B-Stimulant104320126

methcathinone    B-Stimulant104320126

Amphetamine    O
,    O
methamphetamine    O
,    O
and    O
methcathinone    B-Stimulant104320126
are    O
psychostimulant    O
amines    O
that    O
are    O
listed    O
as    O
controlled    O
substances    O
by    O
the    O
US    O
DEA    O
.    O

For    O
example    O
,    O
ephedrine    O
and    O
pseudoephedrine    O
are    O
used    O
to    O
produce    O
methcathinone    B-Stimulant104320126
and    O
methamphetamine    O
.    O

4-Hydroxy-3-methoxymethamphetamine    B-Stimulant104320126

a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine    B-Stimulant104320126

Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine    B-Stimulant104320126

"para"-Iodoamphetamine    B-Stimulant104320126
(    O
PIA    O
)    O

para    O
"-    O
Iodoamphetamine    O
("'PIA    B-Stimulant104320126
)    O
,    O
also    O
known    O
as    O
4-iodoamphetamine    B-Stimulant104320126
(    O
4-IA    B-Stimulant104320126
)    O
,    O
is    O
a    O
research    O
chemical    O
of    O
the    O
phenethylamine    O
and    O
amphetamine    O
chemical    O
classes    O
.    O

THIQ    B-Stimulant104320126

Eskatrol    B-Stimulant104320126
was    O
an    O
amphetamine    O
weight    O
loss    O
agent    O
which    O
was    O
removed    O
by    O
the    O
U.S.    O

Meta-DOT    B-Stimulant104320126
,    O
or    O
5-methylthio-2,4-dimethoxyamphetamine    O
,    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
.    O

4-Methylmethamphetamine    B-Stimulant104320126
(    O
4-MMA    B-Stimulant104320126
)    O
is    O
a    O
putative    O
stimulant    O
and    O
entactogen    O
drug    O
of    O
the    O
amphetamine    B-Stimulant104320126
class    O
.    O

4-Methylmethamphetamine    B-Stimulant104320126

Isopropylamphetamine    B-Stimulant104320126

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    B-Stimulant104320126
,    O
clobenzorex    O
,    O
D-deprenyl    B-Stimulant104320126
,    O
dimethylamphetamine    B-Stimulant104320126
,    O
ethylamphetamine    O
,    O
fencamine    B-Stimulant104320126
,    O
fenethylline    O
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    B-Stimulant104320126
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    B-Stimulant104320126
,    O
selegiline    B-Stimulant104320126
,    O
and    O
tranylcypromine    O
.    O

While    O
most    O
clinically    O
useful    O
TNF    O
inhibitors    O
are    O
monoclonal    O
antibodies    O
,    O
some    O
are    O
simple    O
molecules    O
such    O
as    O
xanthine    O
derivatives    O
(    O
e.g.    O
pentoxifylline    O
)    O
and    O
bupropion    B-Stimulant104320126
.    O
Bupropion    O
is    O
the    O
active    O
ingredient    O
in    O
the    O
smoking    O
cessation    O
aid    O
Zyban    O
and    O
the    O
antidepressants    O
Wellbutrin    O
and    O
Aplenzin    O
.    O

Some    O
of    O
those    O
medicines    O
include    O
:    O
zidovudine    O
(    O
AZT    O
,    O
AIDS    O
)    O
,    O
acyclovir    O
(    O
Zovirax    O
,    O
anti    O
-    O
herpes    O
)    O
,    O
permethrin    O
(    O
Rid    O
,    O
head    O
and    O
body    O
lice    O
)    O
,    O
bupropion    B-Stimulant104320126
(    O
Wellbutrin    O
,    O
antidepressant    O
)    O
,    O
colfosceril    O
palmitate    O
(    O
Exosurf    O
,    O
infant    O
acute    O
respiratory    O
distress    O
)    O
,    O
remifentanil    O
(    O
Ultiva    O
,    O
analgesic    O
/    O
anesthetic    O
)    O
,    O
sumatriptan    O
(    O
Imigran    O
,    O
migraine    O
)    O
,    O
salmeterol    O
(    O
Serement    O
,    O
asthma    O
)    O
,    O
tacrine    O
(    O
Cognex    O
,    O
Alzheimers    O
)    O
,    O
gabapentin    O
(    O
Neurontin    O
,    O
epilepsy    O
and    O
neuropathic    O
pain    O
)    O
,    O
troglitazone    O
(    O
Rezulin    O
,    O
diabetes    O
)    O
,    O
and    O
atorvastatin    O
(    O
Lipitor    O
,    O
cholesterol    O
lowering    O
)    O
.    O

Of    O
medicines    O
,    O
bupropion    B-Stimulant104320126
and    O
varenicline    O
are    O
not    O
legally    O
available    O
in    O
North    O
Korea    O
,    O
but    O
herbal    O
medicines    O
are    O
used    O
as    O
smoking    O
cessation    O
aids    O
.    O

bupropion    B-Stimulant104320126

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
2,5-dimethoxy-4-methylamphetamine    B-Stimulant104320126
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    B-Stimulant104320126
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    B-Stimulant104320126
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

A    O
class    O
action    O
suit    O
has    O
been    O
filed    O
against    O
Biovail    O
by    O
investors    O
who    O
between    O
December    O
14    O
,    O
2006    O
,    O
and    O
July    O
19    O
,    O
2007    O
,    O
bought    O
Biovail    O
stock    O
,    O
alleging    O
that    O
the    O
company    O
had    O
failed    O
to    O
disclose    O
that    O
the    O
multi    O
-    O
dose    O
study    O
on    O
depression    O
drug    O
Aplenzin    B-Stimulant104320126
would    O
not    O
be    O
sufficient    O
for    O
the    O
FDA    O
to    O
approve    O
it    O
.    O

Bupropion    B-Stimulant104320126
(    O
Wellbutrin    O
,    O
Zyban    O
)    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
2,5-dimethoxy-4-methylamphetamine    B-Stimulant104320126
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    O
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    B-Stimulant104320126
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    B-Stimulant104320126
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

As    O
of    O
2013    O
,    O
the    O
10    O
most    O
prescribed    O
psychiatric    O
drugs    O
by    O
number    O
of    O
prescriptions    O
were    O
alprazolam    O
,    O
sertraline    O
,    O
citalopram    O
,    O
fluoxetine    O
,    O
lorazepam    O
,    O
trazodone    O
,    O
escitalopram    O
,    O
duloxetine    O
,    O
bupropion    B-Stimulant104320126
XL    I-Stimulant104320126
,    O
and    O
venlafaxine    O
XR    O
.    O

Bupropion    B-Stimulant104320126
(    O
Wellbutrin    O
)    O
,    O
NDRI    O

Another    O
popular    O
option    O
is    O
to    O
switch    O
to    O
the    O
atypical    O
antidepressant    O
bupropion    B-Stimulant104320126
(    O
Wellbutrin    O
)    O
or    O
to    O
add    O
bupropion    O
to    O
the    O
existing    O
therapy    O
;    O
this    O
strategy    O
is    O
possibly    O
more    O
effective    O
.    O

Bupropion    B-Stimulant104320126
,    O
which    O
is    O
used    O
primarily    O
as    O
an    O
antidepressant    O
and    O
smoking    O
cessation    O
aid    O
,    O
is    O
contraindicated    O
in    O
persons    O
experiencing    O
abrupt    O
withdrawal    O
from    O
benzodiazepines    O
or    O
other    O
sedative    O
-    O
hypnotics    O
(    O
e.g.    O
alcohol    O
)    O
,    O
due    O
to    O
an    O
increased    O
risk    O
of    O
seizures    O
.    O

A    O
bioequivalency    O
profile    O
comparison    O
of    O
150    O
mg    O
extended    O
-    O
release    O
bupropion    B-Stimulant104320126
as    O
produced    O
by    O
Impax    O
Laboratories    O
for    O
Teva    O
and    O
Biovail    O
for    O
GlaxoSmithKline    O
.    O

Medications    O
such    O
as    O
bupropion    B-Stimulant104320126
may    O
also    O
result    O
in    O
tinnitus    O
.    O

Several    O
other    O
medications    O
,    O
often    O
ones    O
originally    O
used    O
in    O
other    O
contexts    O
,    O
have    O
also    O
been    O
shown    O
to    O
be    O
effective    O
including    O
bupropion    B-Stimulant104320126
and    O
modafinil    O
.    O

It    O
was    O
to    O
be    O
sold    O
,    O
when    O
combined    O
with    O
bupropion    B-Stimulant104320126
,    O
under    O
the    O
brand    O
name    O
Empatic    O
,    O
until    O
its    O
development    O
was    O
discontinued    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    B-Stimulant104320126
,    O
bupropion    B-Stimulant104320126
,    O
methoxyphenamine    O
,    O
selegiline    B-Stimulant104320126
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
and    O
DOM    B-Stimulant104320126
(    O
STP    O
)    O
.    O

Bupropion    B-Stimulant104320126
(    O
Zyban    O
,    O
Wellbutrin    O
)    O
-    O
Ganglion    O
blocker    O

Naltrexone    O
is    O
also    O
used    O
in    O
formulation    O
with    O
bupropion    B-Stimulant104320126
(    O
bupropion    O
/    O
naltrexone    O
)    O
to    O
treat    O
obesity    O
in    O
the    O
United    O
States    O
.    O

Commonly    O
used    O
ones    O
are    O
venlafaxine    O
,    O
nefazadone    O
,    O
bupropion    B-Stimulant104320126
,    O
mirtazapine    O
and    O
trazodone    O
.    O

/    O
Yeah    O
,    O
we    O
can    O
get    O
high    O
,    O
and    O
we    O
can    O
get    O
stoned    O
/    O
And    O
we    O
can    O
sniff    O
glue    O
,    O
and    O
we    O
can    O
do    O
E    B-Stimulant104320126
,    O
and    O
we    O
can    O
drop    O
acid    O
.    O
"    O

The    O
lyrics    O
of    O
"    O
Devil    O
Pray    O
"    O
talk    O
about    O
consuming    O
psychoactive    O
drugs    O
like    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
.    O

ATS    O
such    O
as    O
cathinone    O
,    O
MDA    O
,    O
and    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
also    O
fall    O
under    O
this    O
category    O
.    O

The    O
Expert    O
Committee    O
's    O
evaluation    O
of    O
MDMA    B-Stimulant104320126
during    O
its    O
22nd    O
meeting    O
in    O
1985    O
was    O
marked    O
by    O
pleas    O
from    O
physicians    O
to    O
allow    O
further    O
research    O
into    O
the    O
drug    O
's    O
therapeutic    O
uses    O
.    O

MBDB    O
(    O
Methylbenzodioxolylbutanamine    O
)    O
is    O
an    O
entactogen    O
with    O
similar    O
effects    O
to    O
MDMA    B-Stimulant104320126
.    O

The    O
principle    O
synthetic    O
drugs    O
manufactured    O
clandestinely    O
are    O
the    O
amphetamine    O
-    O
type    O
stimulants    O
(    O
ATS    O
)    O
which    O
include    O
the    O
widely    O
abused    O
amphetamine    O
and    O
methamphetamine    O
,    O
as    O
well    O
as    O
the    O
more    O
recently    O
popularized    O
methylenedioxymethamphetamine    O
(    O
MDMA    B-Stimulant104320126
)    O
,    O
known    O
as    O
ecstasy    O
.    O

ecstasy    B-Stimulant104320126
and    O
related    O
designer    O
drugs    O
are    O
under    O
schedule    O
one    O
of    O
the    O
1971    O
Convention    O
,    O
because    O
they    O
have    O
virtually    O
no    O
medical    O
use    O
,    O
while    O
amphetamine    O
and    O
methamphetamine    O
are    O
under    O
schedule    O
2    O
because    O
they    O
began    O
life    O
with    O
medical    O
use    O
.    O

3,4-methylenedioxy-N-methylamphetamine    B-Stimulant104320126
(MDMA)    I-Stimulant104320126

Other    O
notable    O
research    O
he    O
helped    O
carry    O
out    O
includes    O
extensive    O
studies    O
of    O
the    O
structure    O
-    O
activity    O
relationships    O
and    O
mechanisms    O
of    O
action    O
of    O
MDA    O
and    O
MDMA    B-Stimulant104320126
,    O
during    O
which    O
he    O
helped    O
to    O
discover    O
many    O
novel    O
analogues    O
including    O
such    O
compounds    O
as    O
5-methyl-MDA    B-Stimulant104320126
,    O
4-MTA    B-Stimulant104320126
and    O
MDAI    O
.    O

Nichols    O
has    O
said    O
that    O
"    O
he    O
believes    O
gray    O
-    O
market    O
chemists    O
used    O
information    O
from    O
papers    O
he    O
published    O
on    O
4-methylthioamphetamine    B-Stimulant104320126
(    O
MTA    O
)    O
in    O
the    O
1990s    O
to    O
synthesize    O
the    O
drug    O
,    O
which    O
they    O
sold    O
in    O
tablets    O
nicknamed    O
"    O
flatliners    O
"    O
as    O
a    O
substitute    O
for    O
MDMA    B-Stimulant104320126
(    O
Ecstasy    O
)    O
.    O
"    O

Fueled    O
by    O
the    O
increasing    O
demand    O
for    O
drugs    O
in    O
the    O
United    O
States    O
,    O
the    O
country    O
has    O
become    O
a    O
major    O
supplier    O
of    O
heroin    O
,    O
producer    O
and    O
distributor    O
of    O
MDMA    B-Stimulant104320126
,    O
and    O
the    O
largest    O
foreign    O
supplier    O
of    O
cannabis    O
and    O
methamphetamine    O
to    O
the    O
U.S.    O
's    O
market    O
.    O

They    O
begin    O
dating    O
,    O
but    O
Mandy    O
is    O
a    O
bad    O
influence    O
on    O
Aidan    O
and    O
encourages    O
him    O
to    O
skip    O
football    O
practice    O
,    O
get    O
drunk    O
and    O
use    O
ecstasy    B-Stimulant104320126
.    O

The    O
book    O
is    O
a    O
first    O
-    O
person    O
narrative    O
,    O
and    O
revolves    O
around    O
an    O
early    O
mid    O
-    O
life    O
crisis    O
triggered    O
when    O
Tommy    O
"    O
accidentally    O
"    O
proclaims    O
his    O
love    O
for    O
his    O
friend    O
-    O
with    O
-    O
benefits    O
,    O
Charlie    O
,    O
when    O
high    O
on    O
ecstasy    B-Stimulant104320126
.    O

It    O
can    O
detect    O
cannabis    O
,    O
cocaine    O
,    O
crack    O
cocaine    O
,    O
heroin    O
,    O
morphine    O
,    O
amphetamines    O
,    O
MDMA    B-Stimulant104320126
,    O
and    O
benzodiazepines    O
.    O

Additionally    O
,    O
the    O
song    O
suggests    O
the    O
stalker    O
is    O
under    O
the    O
influence    O
of    O
drugs    O
:    O
It    O
must    O
be    O
the    O
weed    O
,    O
it    O
must    O
be    O
the    O
E    B-Stimulant104320126
/    O
'Cause    O
you    O
be    O
poppin    O
'    O
,    O
heard    O
you    O
get    O
it    O
poppin    O
'    O
.    O
"    O

Several    O
notable    O
recreational    O
drugs    O
,    O
such    O
as    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
methamphetamine    O
,    O
and    O
cathinone    O
,    O
are    O
also    O
members    O
of    O
the    O
class    O
.    O

He    O
was    O
arrested    O
along    O
with    O
15    O
people    O
and    O
an    O
actress    O
identified    O
as    O
Yoon    O
on    O
suspicion    O
of    O
supplying    O
ecstasy    B-Stimulant104320126
.    O

She    O
told    O
"    O
Rolling    O
Stone    O
"    O
in    O
2013    O
that    O
it    O
was    O
"    O
the    O
best    O
drug    O
on    O
earth    O
"    O
and    O
called    O
it    O
,    O
along    O
with    O
MDMA    B-Stimulant104320126
,    O
a    O
"    O
happy    O
drug    O
"    O
.    O

He    O
is    O
credited    O
with    O
introducing    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
to    O
psychologists    O
in    O
the    O
late    O
1970s    O
for    O
psychopharmaceutical    O
use    O
and    O
for    O
the    O
discovery    O
,    O
synthesis    O
and    O
personal    O
bioassay    O
of    O
over    O
230    O
psychoactive    O
compounds    O
for    O
their    O
psychedelic    O
and    O
entactogenic    O
potential    O
.    O

He    O
personally    O
tested    O
hundreds    O
of    O
drugs    O
,    O
mainly    O
analogues    O
of    O
various    O
phenethylamines    O
(    O
family    O
containing    O
MDMA    B-Stimulant104320126
,    O
mescaline    O
,    O
and    O
the    O
2C    O
family    O
)    O
,    O
and    O
tryptamines    O
(    O
family    O
containing    O
DMT    O
and    O
psilocin    O
)    O
.    O

”    O
They    O
were    O
charged    O
with    O
murder    O
,    O
laundering    O
millions    O
of    O
dollars    O
obtained    O
from    O
embezzlement    O
at    O
Israel    O
Trade    O
Bank    O
,    O
extortion    O
of    O
business    O
people    O
,    O
and    O
operating    O
an    O
ecstasy    O
-    O
distribution    O
network    O
for    O
millions    O
of    O
ecstasy    B-Stimulant104320126
pills    I-Stimulant104320126
.    O

Two    O
medical    O
students    O
set    O
out    O
to    O
create    O
a    O
drug    O
derived    O
from    O
ecstasy    B-Stimulant104320126
that    O
would    O
enhance    O
and    O
change    O
their    O
personalities    O
.    O

Over    O
dinner    O
,    O
Lily    O
offers    O
Nina    O
an    O
ecstasy    B-Stimulant104320126
capsule    O
to    O
help    O
her    O
relax    O
.    O

In    O
June    O
2010    O
,    O
the    O
band    O
surmounted    O
"    O
technical    O
difficulties    O
due    O
to    O
too    O
much    O
MDMA    B-Stimulant104320126
"    O
while    O
playing    O
a    O
set    O
on    O
The    O
Park    O
Stage    O
at    O
Glastonbury    O
.    O

Rolling    O
is    O
a    O
2007    O
independent    O
drama    O
film    O
about    O
a    O
diverse    O
group    O
of    O
characters    O
who    O
are    O
linked    O
by    O
the    O
drug    O
MDMA    B-Stimulant104320126
(    O
"    O
ecstasy    O
"    O
)    O
.    O

It    O
has    O
been    O
detected    O
in    O
pills    O
touted    O
as    O
legal    O
alternatives    O
to    O
illicit    O
stimulants    O
in    O
New    O
Zealand    O
and    O
pills    O
sold    O
as    O
"    O
ecstasy    B-Stimulant104320126
"    O
in    O
Europe    O
and    O
the    O
United    O
States    O
.    O

Kris    O
tells    O
Sterling    O
that    O
Jasper    O
spent    O
the    O
weekend    O
at    O
home    O
after    O
obtaining    O
the    O
drug    O
Ecstasy    B-Stimulant104320126
and    O
looking    O
to    O
have    O
sex    O
with    O
someone    O
.    O

He    O
tells    O
her    O
that    O
Jasper    O
is    O
at    O
the    O
Ames    O
'    O
island    O
weekend    O
home    O
,    O
that    O
he    O
has    O
obtained    O
the    O
drug    O
Ecstasy    B-Stimulant104320126
and    O
looking    O
to    O
have    O
sex    O
with    O
someone    O
,    O
possibly    O
Rosie    O
.    O

London    O
's    O
crime    O
families    O
are    O
more    O
territorial    O
,    O
but    O
can    O
be    O
internationally    O
active    O
in    O
money    O
laundering    O
as    O
well    O
as    O
drug    O
trafficking    O
,    O
cocaine    O
and    O
ecstasy    B-Stimulant104320126
in    O
particular    O
.    O

In    O
other    O
animal    O
studies    O
,    O
BD1063    O
blocks    O
the    O
effects    O
of    O
MDMA    B-Stimulant104320126
,    O
and    O
reduces    O
alcohol    O
intake    O
in    O
rodent    O
models    O
of    O
alcoholism    O
.    O

MDMA    B-Stimulant104320126
,    O
MDEA    O
,    O
MDA    O

MDMA    B-Stimulant104320126
,    O
MDEA    O
,    O
MDA    O

Leo    O
Zeff    O
(    O
May    O
14    O
,    O
1912    O
-    O
April    O
13    O
,    O
1988    O
)    O
was    O
an    O
American    O
psychologist    O
and    O
psychotherapist    O
in    O
Oakland    O
,    O
California    O
who    O
pioneered    O
the    O
use    O
of    O
LSD    O
,    O
ecstasy    B-Stimulant104320126
(    O
MDMA    O
)    O
,    O
and    O
other    O
psychoactive    O
drugs    O
in    O
psychotherapy    O
in    O
the    O
1970s    O
.    O

3-Methoxyamphetamine    O
has    O
similarly    O
appeared    O
on    O
the    O
illicit    O
market    O
as    O
a    O
designer    O
drug    O
alternative    O
to    O
MDMA    B-Stimulant104320126
,    O
although    O
far    O
more    O
rarely    O
than    O
its    O
infamous    O
positional    O
isomer    O
.    O

During    O
one    O
of    O
the    O
many    O
marital    O
upsets    O
that    O
characterised    O
the    O
Costello    O
household    O
,    O
daughter    O
Chloe    O
retreated    O
upstairs    O
and    O
rifled    O
through    O
older    O
sister    O
Melanie    O
's    O
possessions    O
,    O
finding    O
a    O
stash    O
of    O
MDMA    B-Stimulant104320126
.    O

Spud    O
,    O
Renton    O
and    O
Sick    O
Boy    O
take    O
some    O
Ecstasy    B-Stimulant104320126
and    O
stroll    O
to    O
the    O
Meadows    O
where    O
an    O
excited    O
Sick    O
Boy    O
and    O
Renton    O
try    O
to    O
kill    O
a    O
squirrel    O
but    O
stop    O
after    O
Spud    O
becomes    O
upset    O
by    O
their    O
actions    O
towards    O
the    O
animal    O
.    O

In    O
2012    O
,    O
Jayarah    O
the    O
Truth    O
served    O
a    O
prison    O
sentence    O
for    O
possession    O
of    O
Ecstasy    B-Stimulant104320126
.    O

Retirement    O
-    O
home    O
caregiver    O
Brandi    O
Boski    O
(    O
Mena    O
Suvari    O
)    O
is    O
potentially    O
up    O
for    O
a    O
promotion    O
at    O
work    O
,    O
and    O
celebrates    O
with    O
a    O
night    O
of    O
drinking    O
and    O
Ecstasy    B-Stimulant104320126
before    O
driving    O
home    O
.    O

Reports    O
also    O
alleged    O
that    O
he    O
was    O
under    O
the    O
influence    O
of    O
both    O
ecstasy    B-Stimulant104320126
and    O
hydrocodone    O
.    O

Over    O
parts    O
of    O
the    O
next    O
15    O
years    O
,    O
she    O
used    O
ecstasy    B-Stimulant104320126
,    O
methamphetamine    O
,    O
crack    O
,    O
among    O
others    O
,    O
stating    O
that    O
she    O
turned    O
to    O
drugs    O
because    O
she    O
was    O
"    O
bored    O
"    O
.    O

The    O
IPLO    O
was    O
accused    O
of    O
becoming    O
involved    O
in    O
the    O
illegal    O
drug    O
trade    O
,    O
especially    O
in    O
ecstasy    B-Stimulant104320126
.    O

Three    O
molecules    O
have    O
been    O
found    O
to    O
interact    O
with    O
FAM185a    O
in    O
mice    O
:    O
3,4-methylenedioxymethamphetamine    B-Stimulant104320126
,    O
2,3,7,8-Tetrachlorodibenzodioxin    O
,    O
and    O
benzopyrene    O
.    O

As    O
a    O
consequence    O
of    O
the    O
production    O
of    O
mCPP    O
as    O
a    O
metabolite    O
,    O
patients    O
administered    O
trazodone    O
may    O
test    O
positive    O
on    O
EMIT    O
II    O
urine    O
tests    O
for    O
the    O
presence    O
of    O
MDMA    B-Stimulant104320126
(    O
"    O
ecstasy    O
"    O
)    O
.    O

δH    O
,    O
δC    O
and    O
δN    O
have    O
been    O
used    O
together    O
to    O
analyze    O
tablets    O
of    O
MDA    O
and    O
MDMA    B-Stimulant104320126
and    O
has    O
successfully    O
identified    O
differences    O
which    O
could    O
be    O
used    O
to    O
differentiate    O
between    O
different    O
sources    O
or    O
production    O
mechanisms    O
.    O

Initially    O
,    O
it    O
was    O
believed    O
that    O
Nick    O
had    O
purchased    O
the    O
drug    O
inside    O
club    O
from    O
a    O
dealer    O
,    O
largely    O
due    O
to    O
testimony    O
of    O
his    O
friends    O
,    O
and    O
this    O
led    O
to    O
police    O
and    O
media    O
fears    O
of    O
a    O
"    O
bad    O
"    O
batch    O
of    O
ecstasy    B-Stimulant104320126
,    O
possibly    O
laced    O
with    O
PMA    B-Stimulant104320126
.    O

For    O
comparison    O
,    O
MDAI    O
is    O
similar    O
in    O
potency    O
with    O
releasing    O
serotonin    O
to    O
MDA    O
but    O
significantly    O
less    O
potent    O
than    O
MDMA    B-Stimulant104320126
.    O

The    O
family    O
of    O
drugs    O
typified    O
by    O
MDMA    B-Stimulant104320126
produce    O
their    O
effects    O
through    O
multiple    O
mechanisms    O
of    O
action    O
in    O
the    O
body    O
,    O
and    O
consequently    O
produce    O
three    O
distinct    O
cues    O
which    O
animals    O
can    O
be    O
trained    O
to    O
respond    O
to    O
:    O
a    O
stimulant    O
cue    O
typified    O
by    O
drugs    O
such    O
as    O
methamphetamine    O
,    O
a    O
psychedelic    O
cue    O
typified    O
by    O
drugs    O
such    O
as    O
LSD    O
and    O
DOM    B-Stimulant104320126
,    O
and    O
an    O
"    O
entactogen    O
-    O
like    O
"    O
cue    O
which    O
is    O
produced    O
by    O
drugs    O
such    O
as    O
MDAI    O
and    O
MBDB    O
.    O

Swallowing    O
has    O
been    O
used    O
for    O
the    O
transportation    O
of    O
heroin    O
,    O
cocaine    O
,    O
and    O
MDMA/Ecstasy    B-Stimulant104320126
.    O

Later    O
he    O
discovered    O
that    O
empathogens    O
,    O
such    O
as    O
MDMA    B-Stimulant104320126
,    O
facilitated    O
self    O
-    O
exploration    O
and    O
were    O
helpful    O
in    O
psychological    O
healing    O
when    O
used    O
in    O
conjunction    O
with    O
therapy    O
.    O

Surveys    O
in    O
many    O
countries    O
show    O
that    O
temazepam    O
,    O
MDMA    B-Stimulant104320126
,    O
nimetazepam    O
,    O
and    O
methamphetamine    O
rank    O
among    O
the    O
top    O
illegal    O
drugs    O
most    O
frequently    O
abused    O
.    O

Also    O
,    O
accidental    O
drug    O
overdose    O
was    O
highlighted    O
,    O
with    O
the    O
death    O
of    O
Dolores    O
Molloy    O
's    O
baby    O
Jessica    O
from    O
an    O
accidental    O
Ecstasy    B-Stimulant104320126
overdose    O
when    O
Ross    O
left    O
some    O
ecstasy    O
tablets    O
on    O
the    O
floor    O
of    O
the    O
Molloy    O
household    O
.    O

Further    O
capers    O
ensue    O
as    O
John    O
and    O
Duff    O
try    O
to    O
rob    O
a    O
liquor    O
store    O
and    O
later    O
attempt    O
to    O
con    O
a    O
drug    O
lord    O
out    O
of    O
$    O
30,000    O
by    O
concocting    O
a    O
phony    O
story    O
about    O
running    O
an    O
ecstasy    B-Stimulant104320126
ring    O
.    O

Candy    O
Flip    O
were    O
named    O
after    O
"    O
candyflipping    O
"    O
,    O
the    O
slang    O
term    O
for    O
the    O
practice    O
of    O
taking    O
ecstasy    B-Stimulant104320126
and    O
LSD    O
at    O
the    O
same    O
time    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    B-Stimulant104320126
,    O
bupropion    B-Stimulant104320126
,    O
methoxyphenamine    O
,    O
selegiline    B-Stimulant104320126
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
and    O
DOM    B-Stimulant104320126
(    O
STP    O
)    O
.    O

Being    O
intoxicated    O
on    O
the    O
drug    O
MDMA    B-Stimulant104320126

The    O
five    O
friends    O
become    O
very    O
close    O
,    O
take    O
drugs    O
such    O
as    O
cannabis    O
,    O
ecstasy    B-Stimulant104320126
and    O
cocaine    O
,    O
and    O
"    O
live    O
for    O
the    O
weekend    O
"    O
.    O

Although    O
there    O
is    O
significant    O
dialogue    O
about    O
drug    O
use    O
contained    O
in    O
the    O
film    O
(    O
specifically    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
marijuana    O
,    O
and    O
one    O
sarcastic    O
discussion    O
about    O
heroin    O
and    O
crack    O
cocaine    O
)    O
,    O
the    O
only    O
drug    O
use    O
by    O
main    O
characters    O
is    O
a    O
scene    O
where    O
Jip    O
and    O
Koop    O
are    O
having    O
an    O
intimate    O
conversation    O
at    O
a    O
house    O
party    O
and    O
they    O
are    O
seen    O
cutting    O
up    O
a    O
line    O
of    O
white    O
powder    O
.    O

Other    O
bodies    O
of    O
his    O
work    O
include    O
"    O
Safety    O
in    O
Numbers    O
"    O
(    O
1997    O
)    O
,    O
a    O
bleak    O
study    O
of    O
the    O
ecstasy    B-Stimulant104320126
drug    O
culture    O
in    O
the    O
mid-1990s    O
;    O
"    O
The    O
Indecisive    O
Memento    O
"    O
,    O
a    O
global    O
road    O
trip    O
where    O
the    O
journey    O
itself    O
was    O
the    O
artwork    O
(    O
1999    O
)    O
;    O
"    O
Truth    O
or    O
Consequences    O
"    O
(    O
2001    O
)    O
,    O
a    O
pictorial    O
game    O
based    O
on    O
the    O
history    O
of    O
photography    O
using    O
the    O
town    O
of    O
Truth    O
or    O
Consequences    O
,    O
New    O
Mexico    O
as    O
a    O
backdrop    O
,    O
inspired    O
by    O
the    O
rules    O
of    O
the    O
1950s    O
television    O
show    O
;    O
and    O
"    O
You    O
Love    O
Life    O
"    O
(    O
2005    O
)    O
,    O
in    O
which    O
he    O
uses    O
pictures    O
taken    O
over    O
a    O
20-year    O
period    O
to    O
construct    O
an    O
autobiographical    O
narrative    O
.    O

No    O
stranger    O
to    O
controversy    O
,    O
Sung    O
was    O
caught    O
for    O
using    O
the    O
drug    O
ecstasy    B-Stimulant104320126
in    O
2002    O
,    O
and    O
previously    O
published    O
a    O
book    O
containing    O
nude    O
photographs    O
of    O
herself    O
.    O

LaHood    O
was    O
arrested    O
in    O
June    O
1994    O
for    O
attempting    O
to    O
sell    O
200    O
Ecstasy    B-Stimulant104320126
pills    O
worth    O
$    O
3,600    O
,    O
with    O
a    O
firearm    O
to    O
an    O
undercover    O
police    O
officer    O
.    O

Neurons    O
to    O
Nirvana    O
explores    O
the    O
medicinal    O
properties    O
(    O
biological    O
,    O
emotional    O
and    O
psychological    O
)    O
of    O
Cannabis    O
,    O
Psilocybin    O
,    O
MDMA    B-Stimulant104320126
,    O
LSD    O
and    O
Ayahuasca    O
.    O

Netizens    O
speculated    O
that    O
the    O
victims    O
took    O
the    O
recreational    O
drug    O
called    O
"    O
Green    O
Amore    O
"    O
,    O
a    O
lethal    O
mix    O
of    O
ecstasy    B-Stimulant104320126
and    O
methamphetamine    O
.    O

According    O
to    O
the    O
medico    O
legal    O
report    O
of    O
NBI    O
,    O
it    O
was    O
shown    O
that    O
Fontejon    O
had    O
two    O
types    O
of    O
dangerous    O
drugs    O
in    O
her    O
body    O
:    O
MDMA    B-Stimulant104320126
methylene    O
homolog    O
and    O
synthetic    O
cathinones    O
.    O

The    O
exhibition    O
of    O
the    O
robot    O
's    O
purchases    O
,    O
a    O
landscape    O
of    O
traded    O
goods    O
that    O
included    O
a    O
bag    O
of    O
ten    O
120    O
mg    O
Ecstasy    B-Stimulant104320126
pills    I-Stimulant104320126
"    O
with    O
no    O
bullshit    O
inside    O
"    O
(    O
containing    O
90    O
mg    O
of    O
MDMA    O
)    O
,    O
was    O
staged    O
next    O
-    O
door    O
to    O
a    O
police    O
station    O
near    O
Zürich    O
.    O

Marc    O
and    O
Kay    O
later    O
go    O
to    O
a    O
gay    O
bar    O
,    O
where    O
Marc    O
takes    O
ecstasy    B-Stimulant104320126
.    O

In    O
March    O
2010    O
Chris    O
Houston    O
was    O
served    O
with    O
notice    O
to    O
attend    O
court    O
on    O
charges    O
of    O
supplying    O
ecstasy    B-Stimulant104320126
and    O
cocaine    O
.    O

Australian    O
Federal    O
Police    O
assistant    O
commissioner    O
Neil    O
Gaughan    O
said    O
that    O
"    O
More    O
than    O
1.8    O
tonnes    O
of    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
136    O
kilograms    O
of    O
cocaine    O
and    O
15    O
kg    O
of    O
methamphetamine    O
were    O
stopped    O
from    O
reaching    O
Australian    O
shores    O
.    O

Hallucinogens    O
–    O
Drugs    O
such    O
as    O
LSD    O
,    O
peyote    O
,    O
and    O
MDMA    B-Stimulant104320126
fit    O
in    O
this    O
category    O

Prolactin    O
levels    O
have    O
also    O
been    O
found    O
to    O
rise    O
with    O
use    O
of    O
the    O
drug    O
MDMA    B-Stimulant104320126
.    O

Illegal    O
Stimulant    O
drugs    O
,    O
such    O
as    O
MDMA    B-Stimulant104320126
.    O

Methylenedioxymethamphetamine    B-Stimulant104320126
(    O
MDMA    O
)    O
(    O
ecstasy    O
)    O

After    O
consuming    O
a    O
PMA    B-Stimulant104320126
-    O
containing    O
ecstasy    B-Stimulant104320126
tablet    O
,    O
Ickarus    O
goes    O
into    O
a    O
drug    O
-    O
induced    O
psychosis    O
,    O
eventually    O
finding    O
himself    O
naked    O
in    O
a    O
Berlin    O
hotel    O
where    O
his    O
antics    O
attract    O
the    O
attention    O
of    O
the    O
hotel    O
staff    O
.    O

He    O
becomes    O
associated    O
with    O
several    O
other    O
unsavory    O
teenagers    O
,    O
and    O
is    O
soon    O
tempted    O
into    O
the    O
use    O
of    O
hard    O
drugs    O
like    O
cocaine    O
and    O
ecstasy    B-Stimulant104320126
.    O

Police    O
had    O
also    O
searched    O
the    O
home    O
of    O
freshman    O
defensive    O
end    O
Brandon    O
Joiner    O
,    O
and    O
found    O
marijuana    O
,    O
ecstasy    B-Stimulant104320126
,    O
and    O
hydrocodone    O
.    O

However    O
,    O
Home    O
Secretary    O
Jacqui    O
Smith    O
returned    O
it    O
to    O
Class    O
B    O
in    O
2009    O
,    O
against    O
the    O
council    O
's    O
recommendation    O
,    O
and    O
also    O
declined    O
to    O
follow    O
its    O
recommendation    O
to    O
downgrade    O
ecstasy    B-Stimulant104320126
from    O
Class    O
A    O
to    O
class    O
B.    O

A    O
"    O
Village    O
Voice    O
"    O
review    O
described    O
the    O
autobiographical    O
"    O
Rave    O
Mom    O
"    O
as    O
Magnuson    O
's    O
"    O
travels    O
through    O
1999    O
—    O
a    O
year    O
of    O
Ecstasy    B-Stimulant104320126
-    O
popping    O
,    O
bad    O
romance    O
-    O
chasing    O
and    O
searching    O
for    O
escapism    O
and    O
meaning    O
after    O
her    O
brother    O
's    O
death    O
from    O
AIDS    O
.    O

In    O
April    O
1995    O
in    O
Louisiana    O
,    O
Titus    O
pleaded    O
guilty    O
to    O
conspiracy    O
to    O
possess    O
with    O
intent    O
to    O
distribute    O
ecstasy    B-Stimulant104320126
,    O
and    O
was    O
sentenced    O
to    O
16    O
months    O
'    O
house    O
arrest    O
via    O
monitoring    O
with    O
an    O
electronic    O
anklet    O
.    O

Media    O
reports    O
claim    O
that    O
Rush    O
was    O
using    O
cannabis    O
at    O
the    O
age    O
of    O
15    O
and    O
has    O
used    O
ecstasy    B-Stimulant104320126
and    O
prescription    O
drugs    O
.    O

This    O
is    O
important    O
for    O
the    O
study    O
of    O
the    O
TAAR1    O
receptor    O
,    O
as    O
while    O
numerous    O
other    O
compounds    O
are    O
known    O
which    O
act    O
as    O
TAAR1    O
agonists    O
,    O
such    O
as    O
methamphetamine    O
,    O
MDMA    B-Stimulant104320126
and    O
3-iodothyronamine    O
,    O
all    O
previously    O
known    O
TAAR1    O
agonists    O
are    O
either    O
weak    O
and    O
rapidly    O
metabolized    O
(    O
endogenous    O
ligands    O
)    O
,    O
or    O
have    O
strong    O
pharmacological    O
activity    O
at    O
other    O
targets    O
(    O
amphetamines    O
,    O
thyronamines    O
)    O
,    O
making    O
it    O
very    O
difficult    O
to    O
assess    O
which    O
effects    O
are    O
due    O
to    O
TAAR1    O
activation    O
.    O

Following    O
a    O
series    O
of    O
toasts    O
offered    O
by    O
the    O
guests    O
,    O
Joe    O
distributes    O
the    O
ecstasy    B-Stimulant104320126
Skye    O
brought    O
them    O
as    O
a    O
gift    O
.    O

He    O
was    O
the    O
founder    O
of    O
the    O
now    O
-    O
defunct    O
company    O
Global    O
World    O
Media    O
,    O
a    O
maker    O
of    O
legal    O
intoxicants    O
,    O
Cheyene    O
developed    O
several    O
alternative    O
medicine    O
products    O
,    O
including    O
"    O
Herbal    O
,    O
"    O
an    O
ephedra    O
-    O
based    O
alternative    O
to    O
the    O
drug    O
MDMA    B-Stimulant104320126
,    O
commonly    O
known    O
as    O
"    O
ecstasy    O
.    O
"    O

Herbal    O
is    O
a    O
herbal    O
alternative    O
to    O
the    O
illegal    O
drug    O
MDMA    B-Stimulant104320126
,    O
also    O
known    O
as    O
“    O
ecstasy    B-Stimulant104320126
.    O

Dr.    O
Charles    O
Grob    O
,    O
Professor    O
of    O
Psychiatry    O
and    O
Pediatrics    O
at    O
the    O
UCLA    O
School    O
of    O
Medicine    O
and    O
Director    O
of    O
the    O
Division    O
of    O
Child    O
and    O
Adolescent    O
Psychiatry    O
at    O
Harbor    O
-    O
UCLA    O
Medical    O
Center    O
,    O
conducted    O
a    O
government    O
approved    O
study    O
on    O
MDMA    B-Stimulant104320126
,    O
and    O
confirmed    O
that    O
herbal    O
had    O
nothing    O
in    O
common    O
with    O
the    O
real    O
thing    O
.    O

Fans    O
would    O
bet    O
MDMA    B-Stimulant104320126
tablets    O
as    O
to    O
which    O
song    O
Tomich    O
and    O
Sullivan    O
would    O
begin    O
their    O
quarreling    O
squabbles    O
.    O

The    O
second    O
mission    O
Jimmy    O
assigns    O
to    O
XXXX    O
is    O
to    O
organise    O
the    O
purchase    O
and    O
distribution    O
of    O
one    O
million    O
ecstasy    B-Stimulant104320126
tablets    O
from    O
a    O
low    O
-    O
level    O
gangster    O
who    O
styles    O
himself    O
"    O
The    O
Duke    O
"    O
.    O

The    O
Second    O
Summer    O
of    O
Love    O
is    O
a    O
name    O
given    O
to    O
the    O
period    O
in    O
1988    O
and    O
1989    O
in    O
the    O
United    O
Kingdom    O
,    O
during    O
the    O
rise    O
of    O
acid    O
house    O
music    O
and    O
the    O
euphoric    O
explosion    O
of    O
unlicensed    O
MDMA    B-Stimulant104320126
-    O
fuelled    O
rave    O
parties    O
.    O

The    O
term    O
generally    O
refers    O
to    O
the    O
summers    O
of    O
both    O
1988    O
and    O
1989    O
when    O
electronic    O
dance    O
music    O
and    O
the    O
prevalence    O
of    O
the    O
drug    O
MDMA    B-Stimulant104320126
fuelled    O
an    O
explosion    O
in    O
youth    O
culture    O
culminating    O
in    O
mass    O
free    O
parties    O
and    O
the    O
era    O
of    O
the    O
rave    O
.    O

Dopaminergic    O
stimulants    O
like    O
amphetamine    O
,    O
methamphetamine    O
,    O
cocaine    O
,    O
MDMA    B-Stimulant104320126
,    O
and    O
methylphenidate    O
are    O
euphoriants    O
.    O

Ultimately    O
,    O
the    O
wedding    O
goes    O
off    O
mostly    O
without    O
a    O
hitch    O
(    O
thanks    O
in    O
part    O
to    O
Norman    O
's    O
obliviousness    O
because    O
he    O
took    O
ecstasy    B-Stimulant104320126
)    O
,    O
and    O
Clint    O
edits    O
the    O
video    O
down    O
into    O
a    O
charming    O
(    O
if    O
false    O
)    O
portrayal    O
of    O
a    O
happy    O
wedding    O
.    O

In    O
early    O
July    O
,    O
Richard    O
Pascoe    O
,    O
national    O
and    O
South    O
Australian    O
party    O
president    O
,    O
resigned    O
,    O
citing    O
slumping    O
opinion    O
polls    O
and    O
the    O
poor    O
result    O
in    O
the    O
2006    O
South    O
Australian    O
election    O
as    O
well    O
as    O
South    O
Australian    O
parliamentary    O
leader    O
Sandra    O
Kanck    O
's    O
comments    O
regarding    O
the    O
drug    O
MDMA    B-Stimulant104320126
which    O
he    O
saw    O
as    O
damaging    O
to    O
the    O
party    O
.    O

At    O
the    O
time    O
Baggaley    O
announced    O
he    O
wanted    O
to    O
return    O
to    O
kayaking    O
after    O
serving    O
his    O
suspension    O
,    O
with    O
the    O
comment    O
that    O
after    O
10    O
years    O
of    O
competition    O
"    O
I    O
could    O
seriously    O
do    O
with    O
the    O
rest    O
.    O
"    O
However    O
the    O
Australian    O
Canoe    O
Federation    O
rejected    O
a    O
reinstatement    O
application    O
from    O
Baggaley    O
in    O
October    O
2007    O
after    O
his    O
arrest    O
with    O
hundreds    O
of    O
ecstasy    B-Stimulant104320126
tablets    O
earlier    O
that    O
same    O
year    O
.    O

In    O
February    O
2009    O
,    O
Baggaley    O
pleaded    O
guilty    O
to    O
manufacturing    O
1,509    O
tablets    O
of    O
the    O
drug    O
MDMA    B-Stimulant104320126
and    O
to    O
two    O
counts    O
of    O
supplying    O
a    O
prohibited    O
drug    O
,    O
and    O
was    O
due    O
to    O
be    O
sentenced    O
in    O
March    O
.    O

People    O
using    O
drugs    O
such    O
as    O
MDMA    B-Stimulant104320126
(    O
often    O
referred    O
to    O
colloquially    O
as    O
"    O
Ecstasy    O
"    O
)    O
may    O
overexert    O
themselves    O
,    O
perspire    O
heavily    O
,    O
feel    O
increased    O
thirst    O
,    O
and    O
then    O
drink    O
large    O
amounts    O
of    O
water    O
to    O
rehydrate    O
,    O
leading    O
to    O
electrolyte    O
imbalance    O
and    O
water    O
intoxication    O
–    O
this    O
is    O
compounded    O
by    O
MDMA    O
use    O
increasing    O
the    O
levels    O
of    O
antidiuretic    O
hormone    O
(    O
ADH    O
)    O
,    O
decreasing    O
the    O
amount    O
of    O
water    O
lost    O
through    O
urination    O
.    O

October    O
24    O
,    O
1995    O
:    O
Anna    O
Wood    O
,    O
a    O
15-year    O
-    O
old    O
Australian    O
schoolgirl    O
died    O
from    O
the    O
effects    O
of    O
water    O
intoxication    O
secondary    O
to    O
use    O
of    O
MDMA    B-Stimulant104320126
(    O
commonly    O
known    O
as    O
Ecstasy    O
)    O
.    O

November    O
16    O
,    O
1995    O
:    O
Leah    O
Betts    O
,    O
an    O
English    O
schoolgirl    O
,    O
died    O
as    O
the    O
result    O
of    O
drinking    O
too    O
much    O
water    O
,    O
though    O
in    O
the    O
media    O
her    O
death    O
was    O
initially    O
attributed    O
to    O
taking    O
an    O
ecstasy    B-Stimulant104320126
tablet    O
at    O
her    O
18th    O
birthday    O
party    O
.    O

For    O
instance    O
,    O
reagent    O
kits    O
for    O
testing    O
the    O
purity    O
of    O
ecstasy    O
can    O
be    O
essential    O
now    O
that    O
tablets    O
named    O
ecstasy    B-Stimulant104320126
can    O
in    O
practice    O
contain    O
just    O
about    O
anything    O
,    O
and    O
often    O
do    O
not    O
,    O
in    O
fact    O
,    O
contain    O
MDMA    B-Stimulant104320126
at    O
all    O
.    O
Supplements    O
of    O
vitamins    O
and    O
amino    O
acids    O
have    O
been    O
developed    O
to    O
mitigate    O
specifically    O
the    O
damage    O
of    O
certain    O
illegal    O
drugs    O
.    O

Tryptophan    O
and    O
5-hydroxy    O
-    O
tryptophan    O
,    O
for    O
instance    O
,    O
can    O
be    O
used    O
to    O
help    O
the    O
body    O
replenish    O
serotonin    O
levels    O
in    O
the    O
brain    O
after    O
the    O
use    O
of    O
MDMA    B-Stimulant104320126
,    O
and    O
vitamin    O
supplements    O
are    O
appropriate    O
for    O
users    O
of    O
stimulants    O
such    O
as    O
amphetamine    O
.    O

Anton    O
Köllisch    O
(    O
16    O
March    O
1888    O
–    O
September    O
1916    O
)    O
was    O
a    O
German    O
chemist    O
who    O
,    O
whilst    O
working    O
at    O
Darmstadt    O
for    O
pharmaceutical    O
giant    O
Merck    O
,    O
first    O
described    O
the    O
synthesis    O
of    O
the    O
chemical    O
MDMA    B-Stimulant104320126
which    O
would    O
later    O
come    O
to    O
be    O
known    O
as    O
"    O
ecstasy    O
"    O
.    O

It    O
has    O
been    O
used    O
to    O
study    O
the    O
function    O
of    O
the    O
adenosine    O
A1    O
receptor    O
in    O
animals    O
,    O
which    O
has    O
been    O
found    O
to    O
be    O
involved    O
in    O
several    O
important    O
functions    O
such    O
as    O
regulation    O
of    O
breathing    O
and    O
activity    O
in    O
various    O
regions    O
of    O
the    O
brain    O
,    O
and    O
DPCPX    O
has    O
also    O
been    O
shown    O
to    O
produce    O
behavioural    O
effects    O
such    O
as    O
increasing    O
the    O
hallucinogen    O
-    O
appropriate    O
responding    O
produced    O
by    O
the    O
5-HT2A    O
agonist    O
DOI    B-Stimulant104320126
,    O
and    O
the    O
dopamine    O
release    O
induced    O
by    O
MDMA    B-Stimulant104320126
,    O
as    O
well    O
as    O
having    O
interactions    O
with    O
a    O
range    O
of    O
anticonvulsant    O
drugs    O
.    O

From    O
2003    O
through    O
2007    O
,    O
Palenque    O
Norte    O
produced    O
lectures    O
by    O
pioneering    O
psychedelic    O
explorers    O
Sasha    O
and    O
Ann    O
Shulgin    O
;    O
authors    O
Erik    O
Davis    O
,    O
Jon    O
Hanna    O
,    O
and    O
Daniel    O
Pinchbeck    O
;    O
visionary    O
artists    O
Alex    O
Grey    O
,    O
Allyson    O
Grey    O
,    O
Roberto    O
Venosa    O
,    O
and    O
Martina    O
Hoffmann    O
;    O
origins    O
of    O
life    O
researcher    O
Dr.    O
Bruce    O
Damer    O
;    O
clinical    O
researcher    O
Alicia    O
Danforth    O
;    O
Multidisciplinary    O
Association    O
for    O
Psychedelic    O
Studies    O
president    O
Rick    O
Doblin    O
;    O
MDMA    B-Stimulant104320126
researchers    O
Michael    O
and    O
Annie    O
Mithoefer    O
,    O
and    O
many    O
others    O
.    O

China    O
is    O
a    O
major    O
source    O
of    O
precursor    O
chemicals    O
necessary    O
for    O
the    O
production    O
of    O
cocaine    O
,    O
heroin    O
,    O
MDMA    B-Stimulant104320126
and    O
crystal    O
methamphetamine    O
,    O
which    O
are    O
used    O
by    O
many    O
Southeast    O
Asian    O
and    O
Pacific    O
Rim    O
nations    O
.    O

Because    O
of    O
its    O
increasing    O
popularity    O
with    O
young    O
party    O
goers    O
in    O
Beijing    O
,    O
Shanghai    O
,    O
Nanjing    O
,    O
Guangzhou    O
,    O
and    O
Shenzhen    O
,    O
Chinese    O
law    O
enforcement    O
officials    O
report    O
significant    O
increases    O
in    O
the    O
domestic    O
production    O
of    O
MDMA    B-Stimulant104320126
(    O
"    O
Ecstasy    O
"    O
)    O
.    O

The    O
major    O
drugs    O
of    O
choice    O
are    O
injectable    O
heroin    O
,    O
morphine    O
,    O
smokeable    O
opium    O
,    O
crystal    O
methamphetamine    O
,    O
nimetazepam    O
,    O
temazepam    O
,    O
and    O
MDMA    B-Stimulant104320126
.    O

Scaggs    O
will    O
sometimes    O
get    O
inebriated    O
with    O
the    O
artists    O
he    O
interviews    O
;    O
he    O
did    O
ecstasy    B-Stimulant104320126
with    O
James    O
Blunt    O
.    O

He    O
was    O
reportedly    O
the    O
enforcer    O
and    O
debt    O
collector    O
for    O
drug    O
lord    O
Craig    O
Rodel    O
,    O
whose    O
gang    O
turned    O
in    O
over    O
£    O
50    O
million    O
a    O
year    O
from    O
trafficking    O
cocaine    O
,    O
MDMA    B-Stimulant104320126
,    O
heroin    O
and    O
firearms    O
.    O

24    O
May    O
–    O
BBC1    O
airs    O
the    O
"    O
Everyman    O
"    O
documentary    O
"    O
E    O
is    O
for    O
Ecstasy    O
"    O
,    O
a    O
film    O
exploring    O
the    O
use    O
of    O
the    O
Ecstasy    B-Stimulant104320126
drug    O
in    O
rave    O
culture    O
.    O

Soon    O
afterward    O
,    O
Tobias    O
,    O
under    O
the    O
influence    O
of    O
MDMA    B-Stimulant104320126
,    O
passes    O
out    O
while    O
driving    O
and    O
crashes    O
the    O
van    O
.    O

From    O
his    O
books    O
,    O
it    O
is    O
clear    O
that    O
MDMA    B-Stimulant104320126
or    O
Ecstasy    O
was    O
the    O
drug    O
he    O
found    O
to    O
be    O
most    O
compelling    O
:    O
in    O
his    O
book    O
"    O
Total    O
Synthesis    O
II    O
"    O
,    O
he    O
describes    O
it    O
as    O
"    O
the    O
most    O
benign    O
drug    O
[    O
I    O
have    O
]    O
ever    O
encountered    O
.    O
"    O

MTV    O
noted    O
the    O
pop    O
culture    O
references    O
in    O
"    O
Glass    O
Swords    O
"    O
,    O
namely    O
"    O
Hover    O
Traps    O
"    O
samples    O
the    O
video    O
game    O
"    O
The    O
Legend    O
of    O
Zelda    O
:    O
Ocarina    O
of    O
Time    O
"    O
and    O
the    O
title    O
of    O
"    O
Ultra    O
Thizz    O
"    O
references    O
Bay    O
Area    O
slang    O
for    O
the    O
drug    O
ecstasy    B-Stimulant104320126
.    O

Her    O
main    O
distribution    O
was    O
of    O
the    O
drug    O
ecstasy    B-Stimulant104320126
,    O
and    O
adapted    O
the    O
codename    O
when    O
she    O
absorbed    O
the    O
hero    O
Cloak    O
's    O
darkforce    O
abilities    O
.    O

In    O
July    O
2003    O
,    O
Hardison    O
sent    O
two    O
packages    O
to    O
the    O
U.S.    O
During    O
random    O
inspection    O
at    O
the    O
FedEx    O
hub    O
in    O
Memphis    O
,    O
Tennessee    O
,    O
officials    O
found    O
hidden    O
between    O
pages    O
of    O
a    O
magazine    O
four    O
bags    O
of    O
MDMA    B-Stimulant104320126
,    O
street    O
name    O
Ecstasy    O
,    O
a    O
psychoactive    O
drug    O
used    O
primarily    O
as    O
a    O
recreational    O
drug    O
.    O

Methylenedioxymethamphetamine    B-Stimulant104320126
(    O
MDMA    O
,    O
"    O
ecstasy    O
"    O
)    O

Phenylacetones    O
often    O
play    O
a    O
role    O
in    O
the    O
illicit    O
synthesis    O
of    O
amphetamine    O
and    O
its    O
analogues    O
,    O
3,4-methylenedioxyphenyl-2-propanone    O
(    O
MDP2P    O
)    O
for    O
example    O
being    O
used    O
in    O
the    O
production    O
of    O
3,4-methylenedioxyamphetamine    O
(    O
MDA    O
)    O
,    O
3,4-methylenedioxymethamphetamine    B-Stimulant104320126
(    O
MDMA    O
)    O
,    O

The    O
episode    O
paved    O
the    O
way    O
for    O
Nick    O
's    O
subsequent    O
return    O
to    O
Walford    O
,    O
where    O
he    O
reignited    O
an    O
old    O
feud    O
with    O
Mark    O
Fowler    O
after    O
he    O
discovered    O
Nick    O
was    O
supplying    O
his    O
younger    O
brother    O
Martin    O
with    O
ecstasy    B-Stimulant104320126
.    O

5-Methyl-MDA    B-Stimulant104320126

Etafedrine    B-Stimulant104320126
(    O
INN    O
)    O
or    O
ethylephedrine    B-Stimulant104320126
is    O
a    O
long    O
-    O
acting    O
bronchodilator    O
and    O
has    O
the    O
brand    O
name    O
Nethaprin    B-Stimulant104320126
.    O

It    O
is    O
a    O
higher    O
homologue    O
of    O
4-Methylmethcathinone    B-Stimulant104320126
(    O
Mephedrone    O
)    O
and    O
4-Methylbuphedrone    O
(    O
4-MeMABP    O
)    O
,    O
and    O
the    O
p    O
-    O
Methyl    O
analogue    O
of    O
Pentedrone    B-Stimulant104320126
.    O

Pentedrone    B-Stimulant104320126

Because    O
the    O
2-    O
and    O
5-    O
positions    O
(    O
using    O
phenethylamine    O
numbering    O
scheme    O
,    O
1,5-positions    O
if    O
numbered    O
as    O
benzodifuran    O
)    O
are    O
not    O
equivalent    O
,    O
all    O
unsymmetrical    O
combinations    O
also    O
have    O
two    O
possible    O
positional    O
isomers    O
,    O
with    O
different    O
potencies    O
at    O
the    O
various    O
5-HT2    O
subtypes    O
.    O
Isomeric    O
"    O
Ψ    B-Stimulant104320126
with    O
the    O
oxygens    O
positioned    O
at    O
the    O
2,6-    O
positions    O
,    O
and    O
mescaline    O
analogues    O
with    O
the    O
oxygens    O
at    O
3,5-    O
have    O
also    O
been    O
made    O
,    O
but    O
both    O
are    O
less    O
potent    O
than    O
the    O
corresponding    O
2,5-    O
isomers    O
.    O

It    O
is    O
the    O
levorotatory    O
enantiomer    O
of    O
fenfluramine    B-Stimulant104320126
,    O
the    O
racemic    O
form    O
of    O
the    O
compound    O
,    O
whereas    O
the    O
dextrorotatory    O
enantiomer    O
is    O
dexfenfluramine    B-Stimulant104320126
.    O

Dexfenfluramine    B-Stimulant104320126

It    O
is    O
a    O
racemic    O
mixture    O
of    O
two    O
enantiomers    O
,    O
dexfenfluramine    B-Stimulant104320126
and    O
levofenfluramine    B-Stimulant104320126
.    O

Obetrol    B-Stimulant104320126
,    O
patented    O
by    O
Obetrol    O
Pharmaceuticals    O
in    O
the    O
1950s    O
and    O
indicated    O
for    O
treatment    O
of    O
obesity    O
,    O
was    O
one    O
of    O
the    O
first    O
brands    O
of    O
pharmaceutical    O
methamphetamine    O
products    O
.    O

1-(4-Methylphenyl)-2-aminobutane    B-Stimulant104320126

5-EAPB    B-Stimulant104320126
(    O
1-(benzofuran-5-yl)-"N"-ethylpropan-2-amine    B-Stimulant104320126
)    O
is    O
an    O
entactogenic    O
amphetamine    B-Stimulant104320126
which    O
is    O
structurally    O
related    O
to    O
5-MAPB    B-Stimulant104320126
and    O
5-APB    B-Stimulant104320126
.    O

TOM    B-Stimulant104320126
(psychedelic)    I-Stimulant104320126

"p"-Bromoamphetamine    B-Stimulant104320126

"para"-Hydroxynorephedrine    B-Stimulant104320126

Methylone    B-Stimulant104320126

Bowden    O
's    O
organisation    O
Stargate    O
International    O
began    O
'    O
clinical    O
trials    O
'    O
to    O
distribute    O
EASE    O
,    O
later    O
identified    O
as    O
methylone    B-Stimulant104320126
,    O
after    O
receiving    O
confirmation    O
from    O
the    O
New    O
Zealand    O
Ministry    O
of    O
Health    O
that    O
the    O
product    O
was    O
legal    O
to    O
import    O
and    O
sell    O
.    O

Methylone    B-Stimulant104320126

Smart    O
shops    O
have    O
attempted    O
no    O
further    O
marketing    O
of    O
synthetics    O
since    O
they    O
tried    O
to    O
sell    O
methylone    B-Stimulant104320126
as    O
a    O
"    O
room    O
odorizer    O
"    O
but    O
were    O
ultimately    O
forced    O
to    O
pull    O
it    O
from    O
their    O
shelves    O
in    O
2004    O
,    O
though    O
it    O
can    O
still    O
be    O
obtained    O
under    O
the    O
counter    O
in    O
some    O
shops    O
.    O

UK-414,495    B-Stimulant104320126

It    O
is    O
the    O
α-ethyl    O
analog    O
of    O
MDPEA    O
and    O
MDA    O
and    O
the    O
methylenedioxy    O
analogue    O
of    O
α-ethylphenethylamine    B-Stimulant104320126
.    O

Substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126

Substances    O
that    O
may    O
cause    O
this    O
toxidrome    O
include    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
,    O
cocaine    O
,    O
and    O
phencyclidine    O
.    O

The    O
amphetamine    O
-    O
type    O
stimulants    O
(    O
ATS    O
)    O
,    O
a    O
legal    O
class    O
of    O
stimulants    O
–    O
not    O
all    O
of    O
which    O
are    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
–    O
were    O
defined    O
in    O
the    O
1971    O
treaty    O
and    O
in    O
subsequent    O
revisions    O
.    O

Regarded    O
then    O
as    O
a    O
harmless    O
stimulant    O
,    O
it    O
belongs    O
to    O
the    O
family    O
of    O
drugs    O
called    O
amphetamines    B-Stimulant104320126
,    O
and    O
at    O
that    O
time    O
they    O
were    O
prescribed    O
and    O
used    O
in    O
a    O
very    O
casual    O
way    O
.    O

While    O
still    O
a    O
graduate    O
student    O
,    O
he    O
patented    O
the    O
method    O
that    O
is    O
used    O
to    O
make    O
the    O
optical    O
isomers    O
of    O
hallucinogenic    O
amphetamines    B-Stimulant104320126
.    O

Eventually    O
,    O
García    O
swallowed    O
a    O
large    O
dose    O
of    O
amphetamines    B-Stimulant104320126
and    O
faked    O
a    O
heart    O
attack    O
,    O
in    O
an    O
apparent    O
attempt    O
to    O
cut    O
short    O
his    O
military    O
service    O
.    O

To    O
alleviate    O
her    O
anxiety    O
and    O
chronic    O
insomnia    O
,    O
she    O
began    O
to    O
use    O
barbiturates    O
,    O
amphetamines    B-Stimulant104320126
and    O
alcohol    O
,    O
which    O
also    O
exacerbated    O
her    O
problems    O
,    O
although    O
she    O
did    O
not    O
become    O
severely    O
addicted    O
until    O
1956    O
.    O

For    O
psychosis    O
and    O
schizophrenia    O
,    O
usage    O
of    O
a    O
number    O
of    O
drugs    O
has    O
been    O
associated    O
with    O
development    O
of    O
the    O
disorder    O
,    O
including    O
cannabis    O
,    O
cocaine    O
,    O
and    O
amphetamines    B-Stimulant104320126
.    O

Myanmar    O
is    O
also    O
the    O
world    O
's    O
second    O
largest    O
producer    O
of    O
opium    O
,    O
accounting    O
for    O
25%    O
of    O
entire    O
world    O
production    O
and    O
is    O
a    O
major    O
source    O
of    O
illegal    O
drugs    O
,    O
including    O
amphetamines    B-Stimulant104320126
.    O

All    O
of    O
the    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
and    O
substituted    O
methylenedioxyphenethylamines    O
are    O
substituted    O
phenethylamines    O
as    O
well    O
.    O

Substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126

2,5-Dimethoxy-4-isopropylamphetamine    O
(    O
also    O
known    O
as    O
DOiP    O
and    O
DOiPr    O
)    O
is    O
a    O
psychedelic    O
drug    O
of    O
the    O
phenethylamine    O
and    O
amphetamine    B-Stimulant104320126
chemical    O
classes    O
.    O

In    O
2003    O
,    O
Águila    O
was    O
jailed    O
on    O
drug    O
charges    O
after    O
a    O
policewoman    O
posed    O
as    O
a    O
fan    O
and    O
asked    O
him    O
for    O
amphetamines    B-Stimulant104320126
,    O
after    O
which    O
he    O
gave    O
her    O
two    O
pills    O
.    O

meta    O
"-    O
Methoxyamphetamine    O
(    O
"    O
'    O
MMA    O
)    O
,    O
also    O
known    O
as    O
3-methoxyamphetamine    O
(    O
3-MA    O
)    O
,    O
is    O
a    O
stimulant    O
drug    O
from    O
the    O
amphetamine    B-Stimulant104320126
family    O
.    O

Perry    O
again    O
entered    O
rehab    O
in    O
February    O
2001    O
to    O
treat    O
an    O
addiction    O
to    O
opioids    O
(    O
specifically    O
vicodin    O
and    O
methadone    O
)    O
,    O
amphetamines    B-Stimulant104320126
and    O
alcohol    O
.    O

Some    O
of    O
the    O
prevalent    O
drugs    O
among    O
street    O
children    O
are    O
everyday    O
inhalants    O
(    O
i.e.    O
paint    O
,    O
glue    O
)    O
,    O
marijuana    O
,    O
cough    O
syrup    O
,    O
substituted    B-Stimulant104320126
amphetamines    I-Stimulant104320126
,    O
cocaine    O
,    O
and    O
hallucinogenic    O
teas    O
.    O

Days    O
after    O
the    O
race    O
,    O
the    O
controversy    O
heightened    O
even    O
more    O
,    O
when    O
news    O
broke    O
that    O
Maertens    O
and    O
third    O
-    O
place    O
finisher    O
Walter    O
Planckaert    O
had    O
tested    O
positive    O
for    O
amphetamines    B-Stimulant104320126
and    O
were    O
both    O
disqualified    O
.    O

Levofenfluramine    B-Stimulant104320126
(    O
INN    O
)    O
,    O
or    O
(−)-3-trifluoromethyl-"N"-ethylamphetamine    B-Stimulant104320126
,    O
also    O
known    O
as    O
(−)-fenfluramine    B-Stimulant104320126
or    O
("R")-fenfluramine    B-Stimulant104320126
,    O
is    O
a    O
drug    O
of    O
the    O
amphetamine    B-Stimulant104320126
family    O
that    O
,    O
itself    O
(    O
i.e.    O
,    O
in    O
enantiopure    O
form    O
)    O
,    O
was    O
never    O
marketed    O
.    O

In    O
his    O
first    O
full    O
season    O
however    O
,    O
the    O
1996–97    O
season    O
,    O
as    O
at    O
Derby    O
,    O
he    O
was    O
not    O
a    O
regular    O
,    O
playing    O
in    O
just    O
18    O
matches    O
,    O
and    O
in    O
the    O
following    O
1997–98    O
season    O
,    O
16    O
matches    O
before    O
being    O
suspended    O
after    O
failing    O
a    O
drugs    O
test    O
,    O
testing    O
positive    O
for    O
traces    O
of    O
amphetamines    B-Stimulant104320126
.    O

Dwyer    O
tested    O
positive    O
for    O
amphetamines    B-Stimulant104320126
at    O
the    O
2010    O
NFL    O
Scouting    O
Combine    O
,    O
however    O
it    O
was    O
later    O
ruled    O
exempt    O
by    O
the    O
NFL    O
after    O
it    O
was    O
found    O
that    O
the    O
positive    O
test    O
stemmed    O
from    O
his    O
attention    O
deficit    O
disorder    O
(    O
ADD    O
)    O
medicine    O
.    O

The    O
first    O
death    O
caused    O
by    O
doping    O
at    O
the    O
Olympic    O
Games    O
happened    O
in    O
1960    O
in    O
Rome    O
,    O
when    O
the    O
Danish    O
cyclist    O
Knut    O
Enemark    O
Jensen    O
,    O
who    O
took    O
amphetamines    B-Stimulant104320126
,    O
fell    O
off    O
his    O
bike    O
and    O
died    O
.    O

Having    O
been    O
a    O
long    O
-    O
term    O
heavy    O
user    O
of    O
alcohol    O
and    O
marijuana    O
,    O
Parsons    O
now    O
habitually    O
used    O
cocaine    O
,    O
amphetamines    B-Stimulant104320126
,    O
peyote    O
,    O
mescaline    O
,    O
and    O
opiates    O
as    O
well    O
.    O

Drugs    O
most    O
often    O
associated    O
with    O
this    O
term    O
include    O
:    O
alcohol    O
,    O
cannabis    O
,    O
barbiturates    O
,    O
benzodiazepines    O
,    O
cocaine    O
,    O
methaqualone    O
,    O
opioids    O
and    O
some    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
.    O

Similarly    O
,    O
adopting    O
the    O
view    O
that    O
any    O
(    O
recreational    O
)    O
use    O
of    O
cannabis    O
or    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
constitutes    O
drug    O
abuse    O
implies    O
a    O
decision    O
made    O
that    O
the    O
substance    O
is    O
harmful    O
,    O
even    O
in    O
minute    O
quantities    O
.    O

Flores    O
tested    O
positive    O
for    O
the    O
presence    O
of    O
amphetamines    B-Stimulant104320126
.    O

In    O
1997    O
,    O
Lorraine    O
Molly    O
became    O
addicted    O
to    O
amphetamines    B-Stimulant104320126
to    O
cram    O
for    O
her    O
exams    O
.    O

Kimmage    O
admitted    O
to    O
using    O
amphetamines    B-Stimulant104320126
to    O
ride    O
non    O
-    O
controlled    O
criteriums    O
on    O
a    O
few    O
occasions    O
,    O
and    O
caffeine    O
suppositories    O
,    O
but    O
says    O
he    O
stayed    O
away    O
from    O
more    O
powerful    O
and    O
dangerous    O
drugs    O
that    O
other    O
cyclists    O
were    O
using    O
.    O

On    O
the    O
day    O
of    O
the    O
crime    O
,    O
Mitchell    O
had    O
been    O
spending    O
the    O
day    O
getting    O
high    O
on    O
a    O
mixture    O
of    O
cannabis    O
,    O
alcohol    O
,    O
and    O
amphetamines    B-Stimulant104320126
.    O

Acridorex    O
(    O
INN    O
;    O
BS    O
7573a    O
)    O
is    O
an    O
amphetamine    B-Stimulant104320126
which    O
was    O
investigated    O
as    O
an    O
anorectic    O
but    O
does    O
not    O
appear    O
to    O
have    O
ever    O
been    O
marketed    O
.    O

Oxifentorex    O
(    O
INN    O
)    O
is    O
an    O
amphetamine    B-Stimulant104320126
described    O
as    O
an    O
anorectic    O
which    O
does    O
not    O
appear    O
to    O
have    O
ever    O
been    O
marketed    O
.    O

Fenisorex    O
(    O
INN    O
,    O
USAN    O
,    O
BAN    O
)    O
is    O
an    O
amphetamine    B-Stimulant104320126
-    O
like    O
anorectic    O
drug    O
which    O
does    O
not    O
appear    O
to    O
have    O
ever    O
been    O
marketed    O
.    O

Flucetorex    O
(    O
INN    O
)    O
is    O
an    O
amphetamine    B-Stimulant104320126
which    O
was    O
investigated    O
as    O
an    O
anorectic    O
but    O
does    O
not    O
appear    O
to    O
have    O
ever    O
been    O
marketed    O
.    O

Stimulants    O
such    O
as    O
amphetamines    B-Stimulant104320126
can    O
cause    O
hyperventilation    O
.    O

Users    O
of    O
amphetamines    B-Stimulant104320126
as    O
well    O
as    O
many    O
other    O
pharmacological    O
agents    O
commonly    O
report    O
bruxism    O
as    O
a    O
side    O
-    O
effect    O
;    O
however    O
,    O
it    O
is    O
sometimes    O
mis    O
-    O
referred    O
to    O
as    O
trismus    O
.    O

Catalog    O
products    O
include    O
Drugs    O
-    O
of    O
-    O
Abuse    O
,    O
Pharmaceuticals    O
,    O
Drug    O
Metabolites    O
and    O
Impurities    O
,    O
P450    O
metabolites    O
,    O
Glucuronides    O
,    O
Benzodiazepines    O
,    O
Opiates    O
,    O
Steroids    O
,    O
Amphetamines    B-Stimulant104320126
,    O
Drug    O
Mixes    O
,    O
Nitroglycerins/    O
Explosives    O
,    O
Chemical    O
Warfare    O
by    O
-    O
products    O
,    O
and    O
Phytochemicals    O
.    O

2,5-Dimethoxy-4-iodoamphetamine    B-Stimulant104320126
(    O
DOI    B-Stimulant104320126
)    O
is    O
a    O
psychedelic    O
drug    O
and    O
a    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
.    O

Fenfluramine    O
is    O
a    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
and    O
is    O
also    O
known    O
as    O
3-trifluoromethyl-"N    O
"-    O
ethylamphetamine    O
.    O

MDHOET    O
,    O
or    O
3,4-methylenedioxy    O
-    O
N    O
-    O
hydroxyethylamphetamine    O
,    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
and    O
a    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
.    O

Amfecloral    O
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
amphecloral    O
(    O
USAN    O
)    O
,    O
is    O
a    O
stimulant    O
drug    O
of    O
the    O
phenethylamine    O
and    O
amphetamine    B-Stimulant104320126
chemical    O
classes    O
that    O
was    O
used    O
as    O
an    O
appetite    O
suppressant    O
under    O
the    O
trade    O
name    O
Acutran    O
,    O
but    O
is    O
now    O
no    O
longer    O
marketed    O
.    O

2,5-Dimethoxy-4-fluoroamphetamine    O
(    O
DOF    O
)    O
is    O
a    O
psychedelic    O
drug    O
of    O
the    O
phenethylamine    O
and    O
amphetamine    B-Stimulant104320126
classes    O
.    O
Alexander    O
Shulgin    O

Substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126

That    O
towering    O
work    O
of    O
scholarship    O
laid    O
out    O
most    O
of    O
what    O
has    O
been    O
learned    O
-    O
and    O
selectively    O
forgotten    O
-    O
about    O
heroin    O
,    O
caffeine    O
,    O
nicotine    O
,    O
alcohol    O
,    O
barbiturates    O
,    O
amphetamines    B-Stimulant104320126
,    O
tranquilizers    O
,    O
cocaine    O
,    O
LSD    O
and    O
marijuana    O
.    O

Kirk    O
J.    O
Radomski    O
(    O
born    O
1969    O
)    O
(    O
colloquially    O
known    O
by    O
players    O
as    O
Murdock    O
)    O
is    O
a    O
former    O
batboy    O
and    O
clubhouse    O
employee    O
for    O
the    O
New    O
York    O
Mets    O
Major    O
League    O
Baseball    O
team    O
from    O
1985–1995    O
,    O
who    O
on    O
April    O
27    O
,    O
2007    O
pleaded    O
guilty    O
in    O
United    O
States    O
district    O
court    O
to    O
money    O
laundering    O
and    O
illegal    O
distribution    O
of    O
anabolic    O
steroids    O
,    O
human    O
growth    O
hormone    O
,    O
Clenbuterol    O
,    O
amphetamines    B-Stimulant104320126
and    O
other    O
drugs    O
to    O
"    O
dozens    O
of    O
current    O
and    O
former    O
Major    O
League    O
Baseball    O
players    O
,    O
and    O
associates    O
,    O
on    O
teams    O
throughout    O
Major    O
League    O
Baseball    O
.    O
"    O

3-Fluoromethamphetamine    B-Stimulant104320126
(    O
3-FMA    B-Stimulant104320126
)    O
is    O
a    O
stimulant    O
drug    O
from    O
the    O
amphetamine    B-Stimulant104320126
class    O
that    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
.    O

;    O
Billy    O
:    O
1    O
.    O
Amphetamines    B-Stimulant104320126
(    O
from    O
Billy    O
Whizz    O
,    O
a    O
British    O
comic    O
strip    O
character    O
.    O
)    O
2    O
.    O

As    O
a    O
result    O
,    O
famprofazone    O
has    O
occasionally    O
been    O
implicated    O
in    O
causing    O
positives    O
on    O
drug    O
tests    O
for    O
amphetamine    B-Stimulant104320126
.    O

As    O
a    O
commercial    O
chemical    O
,    O
because    O
it    O
can    O
be    O
used    O
in    O
the    O
illicit    O
production    O
of    O
phenylacetone    O
(    O
used    O
in    O
the    O
manufacture    O
of    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
)    O
,    O
it    O
is    O
subject    O
to    O
controls    O
in    O
countries    O
including    O
the    O
United    O
States    O
and    O
China    O
.    O

DOM    B-Stimulant104320126
(    O
STP    O
)    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
2,5-dimethoxy-4-methylamphetamine    B-Stimulant104320126
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    O
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    B-Stimulant104320126
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    B-Stimulant104320126
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

Some    O
of    O
Shulgin    O
's    O
noteworthy    O
discoveries    O
include    O
compounds    O
of    O
the    O
2C    O
family    O
(    O
such    O
as    O
2C    O
-    O
B    O
)    O
and    O
compounds    O
of    O
the    O
DOx    B-Stimulant104320126
family    I-Stimulant104320126
(    O
such    O
as    O
DOM    B-Stimulant104320126
)    O
.    O

This    O
is    O
reduced    O
to    O
the    O
2-aminoindan    O
following    O
a    O
modification    O
of    O
Nichols    O
'    O
earlier    O
method    O
from    O
a    O
paper    O
discussing    O
DOM    B-Stimulant104320126
analogues    O
,    O
using    O
a    O
Pd    O
/    O
C    O
catalyst    O
in    O
glacial    O
acetic    O
acid    O
with    O
catalytic    O
H2SO4    O
.    O

The    O
family    O
of    O
drugs    O
typified    O
by    O
MDMA    B-Stimulant104320126
produce    O
their    O
effects    O
through    O
multiple    O
mechanisms    O
of    O
action    O
in    O
the    O
body    O
,    O
and    O
consequently    O
produce    O
three    O
distinct    O
cues    O
which    O
animals    O
can    O
be    O
trained    O
to    O
respond    O
to    O
:    O
a    O
stimulant    O
cue    O
typified    O
by    O
drugs    O
such    O
as    O
methamphetamine    O
,    O
a    O
psychedelic    O
cue    O
typified    O
by    O
drugs    O
such    O
as    O
LSD    O
and    O
DOM    B-Stimulant104320126
,    O
and    O
an    O
"    O
entactogen    O
-    O
like    O
"    O
cue    O
which    O
is    O
produced    O
by    O
drugs    O
such    O
as    O
MDAI    O
and    O
MBDB    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    B-Stimulant104320126
,    O
bupropion    B-Stimulant104320126
,    O
methoxyphenamine    O
,    O
selegiline    B-Stimulant104320126
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
and    O
DOM    B-Stimulant104320126
(    O
STP    O
)    O
.    O

4-Ethylamphetamine    B-Stimulant104320126
,    O
a    O
designer    O
drug    O

Desbutal    B-Stimulant104320126

6-APB    B-Stimulant104320126

His    O
contributions    O
include    O
the    O
synthesis    O
and    O
reporting    O
of    O
escaline    O
,    O
LSZ    O
,    O
6-APB    B-Stimulant104320126
,    O
2C    O
-    O
I    O
-    O
NBOMe    O
and    O
other    O
NBOMe    O
variants    O
(    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
D    O
)    O
,    O
and    O
several    O
others    O
,    O
as    O
well    O
as    O
the    O
coining    O
of    O
the    O
term    O
"    O
entactogen    O
"    O
.    O

#    O
Benzfetamine    B-Stimulant104320126

benzphetamine    B-Stimulant104320126

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    B-Stimulant104320126
,    O
clobenzorex    O
,    O
D-deprenyl    B-Stimulant104320126
,    O
dimethylamphetamine    B-Stimulant104320126
,    O
ethylamphetamine    O
,    O
fencamine    B-Stimulant104320126
,    O
fenethylline    O
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    B-Stimulant104320126
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    B-Stimulant104320126
,    O
selegiline    B-Stimulant104320126
,    O
and    O
tranylcypromine    O
.    O

2,3-Methylenedioxyamphetamine    B-Stimulant104320126
(    O
2,3-MDA    O
)    O
,    O
an    O
amphetamine    O
derivative    O
which    O
is    O
mentioned    O
in    O
PIHKAL    O
as    O
a    O
fairly    O
potent    O
and    O
long    O
-    O
lasting    O
stimulant    O
drug    O
,    O
but    O
with    O
little    O
or    O
none    O
of    O
the    O
entactogenic    O
effects    O
associated    O
with    O
its    O
better    O
-    O
known    O
structural    O
isomer    O
MDA    O

4-MTA    B-Stimulant104320126

a-Methyl-4-(methylthio)phenethylamine    B-Stimulant104320126

Flatliner    O
,    O
psychoactive    O
drug    O
4-MTA    B-Stimulant104320126

Madam-6    B-Stimulant104320126
,    O
a    O
psychoactive    O
drug    O

3,4-Ethylidenedioxyamphetamine    B-Stimulant104320126
(    O
EIDA    B-Stimulant104320126
)    O
is    O
a    O
substituted    O
derivative    O
of    O
3,4-methylenedioxyamphetamine    O
(    O
MDA    O
)    O
,    O
which    O
was    O
developed    O
by    O
David    O
Nichols    O
and    O
coworkers    O
,    O
in    O
the    O
course    O
of    O
research    O
to    O
determine    O
the    O
bulk    O
tolerance    O
around    O
the    O
benzodioxole    O
portion    O
of    O
the    O
MDA    O
molecule    O
.    O

It    O
is    O
a    O
higher    O
homologue    O
of    O
4-Methylmethcathinone    B-Stimulant104320126
(    O
Mephedrone    O
)    O
and    O
4-Methylbuphedrone    O
(    O
4-MeMABP    O
)    O
,    O
and    O
the    O
p    O
-    O
Methyl    O
analogue    O
of    O
Pentedrone    B-Stimulant104320126
.    O

mephedrone    B-Stimulant104320126
(    O
4-MMC    O
)    O

As    O
a    O
result    O
,    O
many    O
of    O
them    O
have    O
become    O
controlled    O
substances    O
,    O
which    O
in    O
turn    O
has    O
resulted    O
in    O
the    O
clandestine    O
synthesis    O
of    O
a    O
vast    O
array    O
of    O
designer    O
drugs    O
for    O
the    O
purpose    O
of    O
bypassing    O
drug    O
laws    O
;    O
a    O
prime    O
example    O
of    O
such    O
is    O
the    O
mixed    O
monoamine    O
reuptake    O
inhibitor    O
and    O
releasing    O
agent    O
mephedrone    B-Stimulant104320126
.    O

Drugs    O
,    O
including    O
alcohol    O
,    O
anthracyclines    O
and    O
some    O
other    O
forms    O
of    O
chemotherapy    O
,    O
and    O
antipsychotics    O
,    O
e.g.    O
clozapine    O
,    O
also    O
some    O
designer    O
drugs    O
such    O
as    O
mephedrone    B-Stimulant104320126

It    O
started    O
to    O
be    O
sold    O
online    O
from    O
around    O
2007    O
,    O
but    O
reached    O
peak    O
popularity    O
between    O
about    O
2010    O
-    O
2012    O
,    O
after    O
bans    O
on    O
mephedrone    B-Stimulant104320126
came    O
into    O
effect    O
in    O
various    O
countries    O
.    O

Internet    O
-    O
sourced    O
products    O
claimed    O
to    O
be    O
MDAI    O
have    O
been    O
shown    O
variously    O
to    O
contain    O
mephedrone    B-Stimulant104320126
or    O
other    O
substituted    O
cathinone    O
derivatives    O
,    O
and    O
mixed    O
compositions    O
of    O
inorganic    O
substances    O
,    O
while    O
generally    O
containing    O
no    O
MDAI    O
.    O

In    O
March    O
2010    O
,    O
the    O
ACMD    O
published    O
a    O
report    O
,    O
"    O
Consideration    O
of    O
the    O
cathinones    O
"    O
,    O
which    O
recommended    O
that    O
mephedrone    B-Stimulant104320126
and    O
other    O
cathinones    O
should    O
be    O
made    O
illegal    O
.    O

A    O
sixth    O
member    O
,    O
Dr    O
Polly    O
Taylor    O
,    O
resigned    O
in    O
March    O
2010    O
,    O
shortly    O
before    O
the    O
decision    O
to    O
make    O
substituted    O
cathinones    O
-    O
including    O
the    O
legal    O
high    O
mephedrone    B-Stimulant104320126
-    O
illegal    O
.    O

An    O
inquest    O
at    O
Milton    O
Keynes    O
Coroner    O
's    O
Court    O
resulted    O
in    O
a    O
verdict    O
of    O
death    O
by    O
misadventure    O
after    O
the    O
coroner    O
heard    O
that    O
Webley    O
,    O
who    O
had    O
a    O
history    O
of    O
heart    O
disease    O
,    O
had    O
taken    O
the    O
Class    O
B    O
drug    O
mephedrone    B-Stimulant104320126
prior    O
to    O
the    O
heart    O
attack    O
.    O

formetorex    B-Stimulant104320126
(    O
INN    O
)    O

DOEF    B-Stimulant104320126
,    O
or    O
4-fluoroethyl-2,5-methoxyamphetamine    O
,    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
and    O
of    O
the    O
DOx    B-Stimulant104320126
class    I-Stimulant104320126
.    O

Another    O
was    O
Dexamyl    B-Stimulant104320126
tablets    O
.    O

Dexamyl    B-Stimulant104320126

Several    O
popular    O
products    O
sold    O
by    O
SKF    O
contained    O
amphetamine    O
including    O
Benzedrine    O
pills    O
and    O
inhalers    O
,    O
Dexedrine    B-Stimulant104320126
pills    O
,    O
and    O
Dexamyl    B-Stimulant104320126
tablets    O
.    O

MDPR    B-Stimulant104320126

para    O
"-    O
Methoxyethylamphetamine    O
("'PMEA    B-Stimulant104320126
)    O
,    O
is    O
a    O
stimulant    O
drug    O
related    O
to    O
PMA    B-Stimulant104320126
.    O

Flibanserin    B-Stimulant104320126

Flibanserin    B-Stimulant104320126

Multifunctional    O
serotonin    O
agonist    O
and    O
antagonist    O
;    O
See    O
Flibanserin    B-Stimulant104320126

Shulgin    O
described    O
DOiPR    O
as    O
being    O
at    O
least    O
an    O
order    O
of    O
magnitude    O
weaker    O
than    O
DOPr    B-Stimulant104320126
,    O
with    O
doses    O
of    O
20–30    O
mg    O
required    O
to    O
produce    O
valid    O
changes    O
in    O
mental    O
state    O
.    O

Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine    B-Stimulant104320126

6-Methyl-MDA    B-Stimulant104320126

1-Aminomethyl-5-methoxyindane    O
(    O
AMMI    O
)    O
,    O
is    O
a    O
drug    O
developed    O
by    O
a    O
team    O
led    O
by    O
David    O
E.    O
Nichols    O
at    O
Purdue    O
University    O
,    O
which    O
acts    O
as    O
a    O
selective    O
serotonin    O
releasing    O
agent    O
(    O
SSRA    O
)    O
and    O
binds    O
to    O
the    O
serotonin    O
transporter    O
with    O
similar    O
affinity    O
to    O
DFMDA    B-Stimulant104320126
.    O

It    O
is    O
a    O
racemic    O
mixture    O
of    O
two    O
enantiomers    O
,    O
dexfenfluramine    B-Stimulant104320126
and    O
levofenfluramine    B-Stimulant104320126
.    O

Sibutramine    B-Stimulant104320126
(    O
Reductil    O
,    O
Meridia    O
,    O
Siredia    O
,    O
Sibutrex    O
)    O
is    O
a    O
withdrawn    O
anorectic    O
that    O
itself    O
as    O
a    O
molecule    O
"    O
in    O
vitro    O
"    O
is    O
an    O
SNDRI    O
but    O
preferentially    O
an    O
SDRI    O
,    O
with    O
18.3-    O
and    O
5.8-fold    O
preference    O
for    O
inhibiting    O
the    O
reuptake    O
of    O
serotonin    O
and    O
dopamine    O
over    O
norepinephrine    O
,    O
respectively    O
.    O

Yu    O
was    O
suspended    O
for    O
7    O
months    O
by    O
BWF    O
because    O
one    O
of    O
her    O
sample    O
during    O
2015    O
Summer    O
Universiade    O
contained    O
sibutramine    B-Stimulant104320126
.    O

Meridia    B-Stimulant104320126
(    O
Abbott    O
Laboratories    O
)    O

Bernucci    O
was    O
fired    O
from    O
T    O
-    O
Mobile    O
in    O
September    O
2007    O
after    O
testing    O
positive    O
for    O
Sibutramine    B-Stimulant104320126
.    O

He    O
was    O
battling    O
a    O
weight    O
problem    O
for    O
several    O
years    O
and    O
had    O
been    O
taking    O
Reductil    B-Stimulant104320126
(    O
Sibutramine    O
)    O
,    O
a    O
"    O
slimming    O
pill    O
"    O
,    O
which    O
he    O
said    O
was    O
effective    O
and    O
safe    O
.    O

Barbora    O
Záhlavová    O
-    O
Strýcová    O
's    O
results    O
at    O
the    O
2012    O
Büschl    O
Open    O
were    O
annulled    O
in    O
February    O
2013    O
after    O
the    O
player    O
had    O
committed    O
an    O
anti    O
-    O
doping    O
rule    O
violation    O
on    O
a    O
sample    O
given    O
on    O
16    O
October    O
2012    O
at    O
the    O
Luxembourg    O
Open    O
containing    O
sibutramine    B-Stimulant104320126
.    O

Bis-TOM    B-Stimulant104320126
,    O
or    O
4-methyl-2,5-dimethylthio    O
-    O
alpha    O
-    O
methylphenethylamine    O
,    O
is    O
a    O
lesser    O
-    O
known    O
substituted    B-Stimulant104320126
Amphetamine    I-Stimulant104320126
.    O

In    O
a    O
2015    O
interview    O
with    O
"    O
Rolling    O
Stone    O
"    O
"    O
Magazine    O
"    O
,    O
Pete    O
Townshend    O
referred    O
to    O
"    O
I    O
Ca    O
n't    O
Explain    O
"    O
as    O
"    O
a    O
song    O
,    O
written    O
by    O
some    O
18-year    O
-    O
old    O
kid    O
,    O
about    O
the    O
fact    O
that    O
he    O
ca    O
n't    O
tell    O
his    O
girlfriend    O
he    O
loves    O
her    O
because    O
he    O
's    O
taken    O
too    O
many    O
Dexedrine    B-Stimulant104320126
tablets    O
.    O
"    O

Her    O
socialite    O
mother    O
frequently    O
worried    O
about    O
Brigid    O
's    O
weight    O
and    O
constantly    O
attempted    O
to    O
get    O
her    O
to    O
lose    O
it    O
through    O
any    O
means    O
,    O
from    O
giving    O
her    O
cash    O
for    O
every    O
pound    O
she    O
lost    O
at    O
age    O
11    O
to    O
having    O
the    O
family    O
doctor    O
prescribe    O
amphetamines    O
and    O
dexedrine    B-Stimulant104320126
.    O

The    O
effects    O
of    O
BZP    O
are    O
largely    O
similar    O
to    O
amphetamines    O
,    O
with    O
one    O
study    O
finding    O
that    O
former    O
amphetamine    O
addicts    O
were    O
unable    O
to    O
distinguish    O
between    O
dextroamphetamine    B-Stimulant104320126
and    O
BZP    O
administered    O
intravenously    O
.    O

amphetamine    O
and    O
its    O
isomers    O
(    O
dextroamphetamine    B-Stimulant104320126
and    O
levoamphetamine    B-Stimulant104320126
)    O

Dextroamphetamine    B-Stimulant104320126
(    O
Dexedrine    O
)    O
,    O
the    O
dextro    O
-    O
enantiomer    O
of    O
amphetamine    O

Stephen    O
M.    O
Stahl    O
,    O
renowned    O
academician    O
in    O
psychopharmacology    O
,    O
has    O
stated    O
resorting    O
to    O
a    O
dynamic    O
psychostimulant    O
,    O
in    O
particular    O
,    O
d-amphetamine    B-Stimulant104320126
is    O
the    O
"    O
"    O
classical    O
augmentation    O
strategy    O
"    O
for    O
treatment    O
-    O
refractory    O
depression    O
"    O
.    O

Eskatrol    O
contained    O
dextroamphetamine    B-Stimulant104320126
sulfate    I-Stimulant104320126
and    O
prochlorperazine    O
.    O

SmithKline    O
&    O
French    O
also    O
made    O
Dexedrine    B-Stimulant104320126
and    O
Benzedrine    O
.    O

Following    O
this    O
,    O
he    O
received    O
his    O
PhD    O
degree    O
from    O
the    O
University    O
of    O
Cambridge    O
in    O
1975    O
for    O
an    O
analysis    O
of    O
the    O
behavioural    O
effects    O
of    O
Dextroamphetamine    B-Stimulant104320126
.    O

Several    O
popular    O
products    O
sold    O
by    O
SKF    O
contained    O
amphetamine    O
including    O
Benzedrine    O
pills    O
and    O
inhalers    O
,    O
Dexedrine    B-Stimulant104320126
pills    O
,    O
and    O
Dexamyl    B-Stimulant104320126
tablets    O
.    O

This    O
drug    O
and    O
dextroamphetamine    B-Stimulant104320126
,    O
which    O
was    O
developed    O
from    O
the    O
discovery    O
,    O
have    O
had    O
worldwide    O
medical    O
use    O
as    O
general    O
brain    O
stimulants    O
.    O

In    O
the    O
1920s    O
,    O
both    O
methamphetamine    O
and    O
the    O
dextrorotatory    O
optical    O
isomer    O
of    O
amphetamine    O
,    O
dextroamphetamine    B-Stimulant104320126
,    O
were    O
synthesized    O
.    O

Dexamphetamine    B-Stimulant104320126
,    O

Stimulants    O
such    O
as    O
methylphenidate    O
,    O
caffeine    O
,    O
ephedrine    O
,    O
dextroamphetamine    B-Stimulant104320126
,    O
methamphetamine    O
,    O
and    O
cocaine    O
work    O
against    O
heavy    O
sedation    O
and    O
may    O
elevate    O
mood    O
in    O
distressed    O
patients    O
as    O
do    O
the    O
antidepressants    O
.    O

The    O
raw    O
ingredients    O
used    O
in    O
manufacturing    O
it    O
were    O
d-amphetamine    B-Stimulant104320126
and    O
chloral    O
hydrate    O
.    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
2,5-dimethoxy-4-methylamphetamine    B-Stimulant104320126
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    O
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    B-Stimulant104320126
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    B-Stimulant104320126
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

A    O
MAO    O
-    O
B    O
inhibitor    O
such    O
as    O
selegiline    B-Stimulant104320126
or    O
rasagiline    O
can    O
prevent    O
this    O
from    O
happening    O
.    O

Omigapil    O
was    O
originally    O
developed    O
as    O
a    O
structurally    O
similar    O
molecule    O
to    O
selegiline    B-Stimulant104320126
(    O
L    O
-    O
deprenyl    O
)    O
,    O
a    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAO    O
)    O
blocking    O
the    O
enzyme    O
MAO    O
type    O
B    O
,    O
yet    O
omigapil    O
inhibit    O
neither    O
type    O
of    O
MAO    O
.    O

MAO    O
-    O
B    O
inhibitors    O
(    O
safinamide    O
,    O
selegiline    B-Stimulant104320126
and    O
rasagiline    O
)    O
increase    O
the    O
amount    O
of    O
dopamine    O
in    O
the    O
basal    O
ganglia    O
by    O
inhibiting    O
the    O
activity    O
of    O
monoamine    O
oxidase    O
B    O
(    O
MAO    O
-    O
B    O
)    O
,    O
an    O
enzyme    O
which    O
breaks    O
down    O
dopamine    O
.    O

Agents    O
currently    O
under    O
investigation    O
include    O
anti    O
-    O
apoptotics    O
(    O
omigapil    O
,    O
CEP-1347    O
)    O
,    O
antiglutamatergics    O
,    O
monoamine    O
oxidase    O
inhibitors    O
(    O
selegiline    B-Stimulant104320126
,    O
rasagiline    O
)    O
,    O
promitochondrials    O
(    O
coenzyme    O
Q10    O
,    O
creatine    O
)    O
,    O
calcium    O
channel    O
blockers    O
(    O
isradipine    O
)    O
and    O
growth    O
factors    O
(    O
GDNF    O
)    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    B-Stimulant104320126
,    O
bupropion    B-Stimulant104320126
,    O
methoxyphenamine    O
,    O
selegiline    B-Stimulant104320126
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    B-Stimulant104320126
(    O
ecstasy    O
)    O
,    O
and    O
DOM    B-Stimulant104320126
(    O
STP    O
)    O
.    O

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    B-Stimulant104320126
,    O
clobenzorex    O
,    O
D-deprenyl    B-Stimulant104320126
,    O
dimethylamphetamine    B-Stimulant104320126
,    O
ethylamphetamine    O
,    O
fencamine    B-Stimulant104320126
,    O
fenethylline    O
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    B-Stimulant104320126
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    B-Stimulant104320126
,    O
selegiline    B-Stimulant104320126
,    O
and    O
tranylcypromine    O
.    O

Some    O
of    O
these    O
medicines    O
include    O
selegiline    B-Stimulant104320126
,    O
amantadine    O
,    O
entacapone    O
,    O
dopamine    O
agonists    O
,    O
and    O
anticholinergics    O
(    O
“    O
Movement    O
Disorders    O
”    O
)    O
.    O

Nootropics    O
may    O
enhance    O
cognition    O
,    O
and    O
some    O
newer    O
compounds    O
like    O
NSI-189    O
,    O
9-Me    O
-    O
BC    O
,    O
Dihexa    O
,    O
Selegiline    B-Stimulant104320126
,    O
and    O
Modafinil    O
can    O
produce    O
beneficial    O
cognitive    O
enhancing    O
effects    O
.    O

selegiline    B-Stimulant104320126
(    O
monoamine    O
oxidase    O
inhibitor    O
)    O

5-MAPDI    B-Stimulant104320126
(    O
indanylmethylaminopropane    O
)    O

Counterfeit    O
drugs    O
appeared    O
,    O
trying    O
to    O
violate    O
Alles    O
'    O
'    O
weak    O
'    O
patent    O
,    O
e.g.    O
,    O
"    O
Profetamine    B-Stimulant104320126
"    O
.    O

3-Fluoromethamphetamine    B-Stimulant104320126
(    O
3-FMA    O
)    O

2,5-dimethoxy-4-bromo-"N"-methylamphetamine    B-Stimulant104320126
(    O
Methyl    O
-    O
DOB    O
)    O

He    O
later    O
claimed    O
it    O
was    O
a    O
result    O
of    O
Adderall    B-Stimulant104320126
use    O
and    O
eventually    O
won    O
an    O
appeal    O
,    O
having    O
his    O
suspension    O
lifted    O
.    O

Up    O
to    O
a    O
quarter    O
of    O
college    O
students    O
use    O
Adderall    B-Stimulant104320126
to    O
help    O
them    O
focus    O
on    O
their    O
studies    O
instead    O
of    O
its    O
intended    O
purpose    O
of    O
helping    O
people    O
with    O
ADHD    O
.    O

Adderall    B-Stimulant104320126
use    O
in    O
the    O
video    O
gaming    O
industry    O
has    O
been    O
receiving    O
more    O
and    O
more    O
attention    O
in    O
recent    O
years    O
.    O

After    O
a    O
player    O
publicly    O
admitted    O
Adderall    B-Stimulant104320126
use    O
following    O
ESL    O
One    O
Katowice    O
2015    O
,    O
ESL    O
worked    O
with    O
the    O
National    O
Anti    O
-    O
Doping    O
Agency    O
and    O
the    O
World    O
Anti    O
-    O
Doping    O
Agency    O
to    O
institute    O
an    O
anti    O
-    O
drug    O
policy    O
.    O

Clonidine    O
has    O
also    O
been    O
successfully    O
used    O
in    O
indications    O
that    O
exceed    O
what    O
would    O
be    O
expected    O
from    O
a    O
simple    O
blood    O
-    O
pressure    O
lowering    O
drug    O
:    O
it    O
has    O
recently    O
shown    O
positive    O
results    O
in    O
children    O
with    O
ADHD    O
who    O
suffer    O
from    O
tics    O
resulting    O
from    O
the    O
treatment    O
with    O
a    O
CNS    O
stimulant    O
drug    O
,    O
such    O
as    O
Adderall    B-Stimulant104320126
XR    I-Stimulant104320126
or    O
methylphenidate    O
;    O
clonidine    O
also    O
helps    O
alleviate    O
symptoms    O
of    O
opioid    O
withdrawal    O
.    O

In    O
2013    O
,    O
he    O
began    O
the    O
season    O
with    O
a    O
25-game    O
suspension    O
for    O
using    O
Adderall    B-Stimulant104320126
,    O
and    O
subsequently    O
spent    O
time    O
on    O
the    O
disabled    O
list    O
,    O
ultimately    O
playing    O
in    O
fewer    O
than    O
100    O
games    O
for    O
the    O
first    O
time    O
in    O
his    O
MLB    O
career    O
.    O

On    O
November    O
27    O
,    O
2012    O
,    O
Ruiz    O
was    O
suspended    O
for    O
25    O
games    O
without    O
pay    O
by    O
the    O
MLB    O
for    O
testing    O
positive    O
for    O
an    O
amphetamine    O
called    O
Adderall    B-Stimulant104320126
.    O

Adderall    B-Stimulant104320126

Mixed    B-Stimulant104320126
amphetamine    I-Stimulant104320126
salts    I-Stimulant104320126
(    O
Adderall    O
)    O
,    O
a    O
3:1    O
mix    O
of    O
dextro    O
/    O
levo    O
-    O
enantiomers    O
of    O
amphetamine    O

In    O
2013    O
,    O
Lichtenberg    O
designed    O
a    O
line    O
of    O
sweatshirts    O
similar    O
to    O
American    O
football    O
jerseys    O
for    O
the    O
Los    O
-    O
Angeles    O
based    O
boutique    O
Kitson    O
,    O
but    O
with    O
the    O
names    O
of    O
pharmaceutical    O
drugs    O
"    O
Adderall    B-Stimulant104320126
"    O
,    O
"    O
Vicodin    O
"    O
and    O
"    O
Xanax    O
"    O
across    O
the    O
backs    O
at    O
shoulder    O
level    O
with    O
a    O
two    O
-    O
digit    O
-    O
number    O
.    O

She    O
logs    O
the    O
ups    O
and    O
downs    O
of    O
medications    O
such    O
as    O
Adderall    B-Stimulant104320126
and    O
Provigil    O
;    O
she    O
looks    O
at    O
dietary    O
supplements    O
and    O
biofeedback    O
.    O
…    O

Chris    O
Davis    O
of    O
the    O
Baltimore    O
Orioles    O
is    O
suspended    O
for    O
25    O
games    O
without    O
pay    O
for    O
testing    O
positive    O
for    O
the    O
amphetamine    O
Adderall    B-Stimulant104320126
.    O

Smart    O
shops    O
(    O
often    O
webshops    O
)    O
offer    O
prescription    O
-    O
free    O
pharmacy    O
products    O
sold    O
as    O
Ritalin    O
,    O
Adderall    B-Stimulant104320126
,    O
and    O
modafinil    O
,    O
for    O
example    O
.    O

2-Fluoroamphetamine    O
differs    O
from    O
3-    B-Stimulant104320126
and    O
4-fluoroamphetamine    B-Stimulant104320126
in    O
the    O
position    O
of    O
the    O
fluorine    O
atom    O
on    O
the    O
aromatic    O
ring    O
,    O
making    O
them    O
positional    O
isomers    O
of    O
one    O
another    O
.    O

4-Fluoroamphetamine    B-Stimulant104320126
(    O
4-FA    O
)    O

MDBU    B-Stimulant104320126
,    O
or    O
3,4-methylenedioxy    O
-    O
N    O
-    O
butylamphetamine    O
,    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
.    O

Methyl    O
-    O
DMA    O
,    B-Stimulant104320126
or    I-Stimulant104320126
2,5-dimethoxy-N-methylamphetamine    I-Stimulant104320126
,    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
.    O

6-APT    B-Stimulant104320126
(    O
6-(2-aminopropyl)tetralin    O
)    O

Muira    B-Stimulant104320126
puama    I-Stimulant104320126
extract    O
(    O
stem    O
)    O

Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine    B-Stimulant104320126

Specifically    O
these    O
include    O
5-APB    B-Stimulant104320126
,    O
6-APB    B-Stimulant104320126
,    O
5-APDB    O
,    O
6-APDB    O
and    O
their    O
N    O
-    O
methyl    O
derivatives    O
5-MAPB    B-Stimulant104320126
,    O
6-MAPB    B-Stimulant104320126
,    O
5-MAPDB    B-Stimulant104320126
and    O
6-MAPDB    B-Stimulant104320126
,    O
as    O
well    O
as    O
5-IT    O
and    O
its    O
isomer    O
6-IT    O
,    O
plus    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C    O
-    O
I    O
and    O
NBOMe-2C    O
-    O
D.    O

5-APB    B-Stimulant104320126

Chlorphentermine    B-Stimulant104320126

Chlorphentermine    B-Stimulant104320126

Chlorphentermine    B-Stimulant104320126

A    O
formulation    O
sold    O
in    O
the    O
1980s    O
was    O
made    O
with    O
the    O
sympathomimetic    O
cinnamedrine    B-Stimulant104320126
.    O

3-Fluoroamphetamine    B-Stimulant104320126
(    O
3-FA    O
)    O

2-Bromo-4,5-methylenedioxyamphetamine    B-Stimulant104320126
(    O
6-Bromo-MDA    B-Stimulant104320126
)    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
and    O
a    O
substituted    B-Stimulant104320126
amphetamine    I-Stimulant104320126
.    O

PF-219,061    B-Stimulant104320126
is    O
a    O
drug    O
that    O
was    O
under    O
development    O
by    O
Pfizer    O
which    O
acts    O
as    O
a    O
potent    O
and    O
highly    O
selective    O
agonist    O
for    O
the    O
dopamine    O
D3    O
receptor    O
.    O

PF-219,061    B-Stimulant104320126

On    O
7    O
June    O
,    O
the    O
PNP    O
Crime    O
Laboratory    O
confirmed    O
that    O
the    O
amphetamine    O
-    O
based    O
metabolites    O
"para"-Methoxyamphetamine    B-Stimulant104320126
and    O
methylenedioxyamphetamine    B-Stimulant104320126
were    O
found    O
on    O
the    O
bodies    O
of    O
Migawa    O
and    O
Miller    O
,    O
in    O
addition    O
to    O
traces    O
of    O
methylenedioxycathinone    O
found    O
on    O
Migawa    O
.    O

Methylenedioxyamphetamine    B-Stimulant104320126
(    O
MDA    O
)    O

2,5-Dimethoxy-4-butylamphetamine    B-Stimulant104320126
(    O
DOBU    O
)    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
and    O
a    O
substituted    B-Stimulant104320126
Amphetamine    I-Stimulant104320126
.    O

This    O
parallels    O
Alexander    O
Shulgin    O
's    O
finding    O
that    O
EDMA    B-Stimulant104320126
(    O
the    O
1,4-benzodioxine    O
analogue    O
of    O
6-APT    O
)    O
is    O
inactive    O
,    O
and    O
appears    O
to    O
indicate    O
that    O
the    O
pharmacokinetics    O
of    O
both    O
EDMA    O
and    O
6-APT    O
may    O
not    O
be    O
favorable    O
.    O

MEE    B-Stimulant104320126
,    O
or    O
2-methoxy-4,5-diethoxyamphetamine    O
,    O
is    O
a    O
lesser    O
-    O
known    O
psychedelic    O
drug    O
.    O

2,5-Dimethoxy-4-Substituted    B-Stimulant104320126
Amphetamine    I-Stimulant104320126

2,5-Dimethoxy-4-Substituted    B-Stimulant104320126
Amphetamine    I-Stimulant104320126

4-substituted-2,5-Dimethoxyamphetamines    B-Stimulant104320126
(    O
'    O
"    O
DO"x    O
)    O
is    O
a    O
chemical    O
class    O
of    O
substituted    O
amphetamine    O
derivatives    O
featuring    O
methoxy    O
groups    O
at    O
the    O
2-    O
and    O
5-    O
positions    O
of    O
the    O
phenyl    O
ring    O
,    O
and    O
a    O
substituent    O
such    O
as    O
alkyl    O
or    O
halogen    O
at    O
the    O
4-    O
position    O
of    O
the    O
phenyl    O
ring    O
.    O

DOx    B-Stimulant104320126
,    O
2,5-dimethoxy    O
,    O
4-substituted    O
amphetamines    O

Mannish    B-Stimulant104320126
Water    I-Stimulant104320126

DOI    O
is    O
not    O
scheduled    O
in    O
the    O
United    O
States    O
,    O
but    O
it    O
is    O
likely    O
that    O
DOI    O
would    O
be    O
considered    O
an    O
analog    O
(    O
of    O
DOB    B-Stimulant104320126
)    O
,    O
in    O
which    O
case    O
,    O
sales    O
or    O
possession    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analogue    O
Act    O
.    O

DOB    B-Stimulant104320126

DOB    B-Stimulant104320126

DOF    O
rather    O
resembles    O
the    O
4-unsubstituted    O
2,5-dimethoxyamphetamine    O
than    O
DOC    B-Stimulant104320126
,    O
DOB    B-Stimulant104320126
or    O
DOI    B-Stimulant104320126
.    O

Indanylaminopropane    B-Stimulant104320126

3,4-Dichloroamphetamine    B-Stimulant104320126
(    O
DCA    B-Stimulant104320126
)    O
,    O
is    O
an    O
amphetamine    O
derived    O
drug    O
invented    O
by    O
Eli    O
Lilly    O
in    O
the    O
1960s    O
,    O
which    O
has    O
a    O
number    O
of    O
pharmacological    O
actions    O
.    O

3,4-Methylenedioxy-"N"-isopropylamphetamine    B-Stimulant104320126
(    O
MDIP    B-Stimulant104320126
,    O
MDIPA    B-Stimulant104320126
)    O
is    O
a    O
psychoactive    O
drug    O
of    O
the    O
phenethylamine    O
and    O
amphetamine    O
chemical    O
classes    O
which    O
acts    O
as    O
an    O
entactogen    O
,    O
psychedelic    O
,    O
and    O
stimulant    O
.    O

DOF    O
rather    O
resembles    O
the    O
4-unsubstituted    O
2,5-dimethoxyamphetamine    O
than    O
DOC    B-Stimulant104320126
,    O
DOB    B-Stimulant104320126
or    O
DOI    B-Stimulant104320126
.    O

#    O
Levamfetamine    B-Stimulant104320126

The    O
drug    O
contained    O
the    O
racemic    O
mixture    O
of    O
amphetamine    O
,    O
which    O
is    O
an    O
equal    O
parts    O
mixture    O
of    O
levoamphetamine    B-Stimulant104320126
and    O
dextroamphetamine    B-Stimulant104320126
.    O

amphetamine    O
and    O
its    O
isomers    O
(    O
dextroamphetamine    B-Stimulant104320126
and    O
levoamphetamine    B-Stimulant104320126
)    O

Thus    O
,    O
while    O
several    O
-    O
fold    O
less    O
potent    O
than    O
its    O
analogues    O
2-methyl-MDA    B-Stimulant104320126
and    O
5-methyl-MDA    B-Stimulant104320126
,    O
and    O
approximately    O
half    O
as    O
potent    O
as    O
MDA    O
,    O
6-methyl    O
-    O
MDA    O
is    O
still    O
significantly    O
active    O
,    O
and    O
appropriate    O
doses    O
may    O
be    O
similar    O
to    O
or    O
somewhat    O
higher    O
than    O
those    O
of    O
MDMA    O
.    O

dimethylamphetamine    B-Stimulant104320126

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    B-Stimulant104320126
,    O
clobenzorex    O
,    O
D-deprenyl    B-Stimulant104320126
,    O
dimethylamphetamine    B-Stimulant104320126
,    O
ethylamphetamine    O
,    O
fencamine    B-Stimulant104320126
,    O
fenethylline    O
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    B-Stimulant104320126
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    B-Stimulant104320126
,    O
selegiline    B-Stimulant104320126
,    O
and    O
tranylcypromine    O
.    O

2,3,4,5-Tetramethoxyamphetamine    B-Stimulant104320126
(    O
TA    O
,    O
TeMA    O
)    O

4-Fluoromethamphetamine    B-Stimulant104320126
(    O
4-FMA    O
)    O

4-Fluoromethamphetamine    B-Stimulant104320126
(    O
4-FMA    O
)    O


